Document:

<Page>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

                                                                   EXHIBIT 10.20

                   COLLABORATIVE SOLUTIONS PROVIDER AGREEMENT

     This Collaborative Solutions Provider Agreement ("Agreement") is entered
into as of July 10, 2001 (the "Effective Date") by and between Bergen Brunswig
Drug Company, a California corporation ("Bergen") and Omnicell.com, a California
corporation ("Omnicell").

                                    RECITALS

     WHEREAS, Omnicell is a provider of clinical infrastructure and workflow
automation solutions for the healthcare industry;

     WHEREAS, Bergen is a wholesale distributor of pharmaceutical products and
provider of other goods and services;

     WHEREAS, the parties hereto desire to enter into this Agreement for the
purpose of setting forth the terms and conditions whereby Omnicell and Bergen
shall collaborate to jointly market one another's products and services and to
leverage their respective strengths in supply automation and hospital pharmacy
to compete more effectively in the automation and drug distribution
marketplaces.

                                    AGREEMENT

     NOW, THEREFORE, in consideration of the mutual covenants of the parties set
forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by the parties, the parties agree
as follows:

1. COLLABORATION ACTIVITIES.

     1.1 Omnicell is in the business of providing clinical infrastructure and
workflow automation solutions. Omnicell's offerings include: Omnicell pharmacy
system, Sure-Med pharmacy system, supply systems and combination systems.

          The Omnicell and Sure-Med pharmacy systems, together with all other
future and existing products, modifications, enhancements, revisions and
upgrades thereof shall be referred to as the "Omnicell Products".

     1.2 Omnicell and Bergen will use commercially reasonable efforts to
collaborate in identifying, targeting and providing business opportunities to
prospective and existing customer accounts, including exchanging customer lists
(each on a strictly confidential basis), mutually analyzing and prioritizing
sales opportunities and conducting no less than quarterly meetings to effect the
purposes of this Agreement.

     1.3 The parties contemplate that the marketplace for their respective
products will from time-to-time require bundled offerings of automation, drug
distribution, and in some cases, e-commerce platforms (collectively, "Bundled
Offering" or "Bundled Offerings").

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       1

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

     1.4 Bergen and Omnicell each have certain software platforms currently
known as InterLinx(TM) COE and OmniBuyer(TM), respectively, as the same exist or
may be changed or replaced from time to time (collectively, the "Software
Platforms"), which the parties intend to utilize on a customer-by-customer basis
as part of a Bundled Offering pursuant to terms and conditions of a separately
negotiated written agreement.

     1.5 In the event either party receives from a customer or prospective
customer a request for proposal, whether formal or informal, verbal or written
(each, an "RFP") which contemplates a Bundled Offering, the party receiving the
RFP shall promptly notify in writing the other party and communicate the details
of the RFP to the other party. Such other party will have the absolute right of
first refusal to participate in responding to the RFP. If the other party does
not indicate within thirty (30) days of receipt of notice of the RFP its desire
to participate in responding to the RFP, such party will be deemed to have
waived its right to participate.

     1.6 In the event a customer or prospective customer of either party has
requested a Bundled Offering or the parties have identified a customer for which
a Bundled Offering will be initiated, each party commits to use its commercially
reasonable efforts and provide adequate resources to collaborate with the other
party in good faith to create a Bundled Offering that has greater value to the
customer or prospective customer than the sum of the respective individual
offerings of Omnicell and Bergen. In such circumstances, neither Omnicell nor
Bergen shall negotiate outside the Bundled Offering with the customer unless the
other consents prior to such separate negotiations.

     1.7 Subject to the goals set forth in Subsection 1.6 above, each party will
have sole discretion and control over the final price structure for its
respective products and services whether or not included within a Bundled
Offering. In all circumstances, any prospective customer shall be given the
option of selecting either party's individual offering for automation and drug
distribution, respectively.

     1.8 Any development will be limited to ensuring that both companies'
e-commerce products and Software Platforms interface effectively. Any
development or integration of the party's e-commerce and Software Platforms,
each subject to the mutual approval(s) of the parties, shall be by separate
written agreements and under such terms and conditions as agreed upon by the
Chief Information Officer or Chief Technology Officer, as applicable, of each
respective company. Development of any new products will be discussed and
mutually agreed upon individually and as requested by customers.

     1.9 The designated Marketing Executives of each company shall meet annually
to plan the scope of joint marketing activities and approve a joint marketing
budget for purposes of this Agreement and the amount of marketing dollars
Omnicell will make available to Bergen for additional marketing activities. In
addition, each party shall make available to the other at no charge a sufficient
number of brochures and other printed materials.

2. SCOPE OF AGREEMENT.

     The relationship of the parties shall be as set forth in Schedule A.

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       2

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

3. OBLIGATIONS OF BERGEN.

     3.1 Bergen shall from time to time and upon request of Omnicell provide to
Omnicell such information as Bergen deems appropriate describing Bergen's
products and services.

     3.2 Bergen will be solely responsible for providing to joint customers of
Omnicell and Bergen all drug distribution and related services and support.

     3.3 Bergen shall be solely responsible for all compensation to Bergen's
sales and other Bergen personnel.

     3.4 Subject to the other provisions of this Agreement, Bergen in its sole
but reasonable discretion will utilize the resources of its National Health
Systems sales force, Pharmacy Business Solutions consulting group and/or such
other resources as it deems appropriate to carry out its obligations under this
Agreement.

     3.5 Bergen shall designate certain personnel (as the same may be changed
from time-to-time in Bergen's sole but reasonable discretion) for each of the
designated functions in order to carry out the purposes of this Agreement:

          STRATEGIC EXECUTIVE - responsible for the definitive agreements,
          corporate relationship and joint development efforts and project
          expansion.

          SALES EXECUTIVE - responsible for handling joint RFP's, prioritizing
          customer opportunities, sales training on Bergen sales force and
          consultants and ongoing solutions development.

          MARKETING EXECUTIVE - responsible for project support and providing
          sales support, marketing studies and related materials.

     3.6 During the Term of this Agreement, Bergen will commit to service level
commitments in those hospitals and health systems where Omnicell and Bergen have
a joint customer relationship that arose as a result of a Bundled Offering of
Omnicell and Bergen.

4. OBLIGATIONS OF OMNICELL.

     4.1 Omnicell shall from time to time and upon request of Bergen provide to
Bergen such information as Omnicell deems appropriate describing Omnicell's
products and services.

     4.2 Omnicell will be solely responsible for providing all installations of
Omnicell Products and ongoing service support.

     4.3 Omnicell shall be solely responsible for all compensation to Omnicell's
sales and other Omnicell personnel.

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       3

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

     4.4 Subject to the other provisions of this Agreement, Omnicell in its sole
but reasonable discretion will utilize the resources of its national sales force
and/or such other resources as it deems appropriate to carry out its obligations
under this Agreement.

     4.5 Omnicell shall designate personnel (as the same may be changed from
time-to-time in Omnicell's sole but reasonable discretion) for each of the
designated functions in order to carry out the purposes of this Agreement:

          STRATEGIC EXECUTIVE - responsible for the definitive agreements,
          corporate relationship and joint development efforts and project
          expansion.

          SALES EXECUTIVE - responsible for handling joint RFP's, prioritizing
          customer opportunities, sales training on Omnicell's sales force and
          consultants and ongoing solutions development.

          MARKETING EXECUTIVE - responsible for project support and providing
          sales support, marketing studies and related materials.

     4.6 During the Term (as defined herein) of this Agreement, Omnicell will
use its best efforts to have trained service and other certified personnel in
all geographic areas where its automation is utilized and will use its
commercially reasonable efforts to have its personnel in those geographic areas
where Omnicell and Bergen have a joint customer relationship that arose as a
result of a Bundled Offering of Omnicell and Bergen.

5. CERTAIN REMUNERATION.

     The parties shall have those obligations as set forth in Schedule B.

6. TERM.

     6.1 The Term of this Agreement shall commence on the Effective Date of this
Agreement and shall continue for a period of five years, unless otherwise
terminated as provided herein ("Initial Term"). This Agreement may be extended
for additional five (5) year terms as mutually agreed upon in writing between
the parties (collectively with the Initial Term, as the "Term"). Either party
may terminate this immediately upon the occurrence of either of the following
events (a termination for cause):

          6.1.1     the failure by a party to cure a material breach of this
                    Agreement within thirty (30) days of written notice thereof,
                    or

          6.1.2     upon the (i) filing of an application by a party to this
                    Agreement for, or its consent to, the appointment of a
                    trustee, receiver, or custodian of its assets; (ii) the
                    entry of an order for relief with respect to a party in
                    proceedings under the United States Bankruptcy Code, as
                    amended or superseded from time to time; (iii) the making by
                    a party of any general assignment for the benefit of
                    creditors; (iv) the entry of an

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       4

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

                    order, judgment, or decree by any court of competent
                    jurisdiction appointing a trustee, receiver, or custodian of
                    the assets of a party unless the proceedings and the person
                    appointed are dismissed within ninety (90) days; or (v) the
                    failure by a party generally to pay its debts as the debts
                    become due within the meaning of Section 303(h)(1) as
                    amended or superseded from time to time, of the United
                    States Bankruptcy Code, as determined by a bankruptcy court,
                    or in the event of a party's admission in writing of its
                    inability to pay its debts as they become due.

     6.2 The parties rights set forth in this Section 6 are in addition to any
other rights or remedies available herein, at law, in equity or otherwise.

     6.3 Upon termination of this Agreement for any reason and upon request of
the other party each party shall immediately return to the other party any
Confidential Information of the other party that it has in its possession.

7. USE OF TRADEMARKS.

     7.1 During the Term of this Agreement, Bergen may use, only in connection
with Bergen's marketing and promotion of the Omnicell Products, trademarks,
insignias, logos, proprietary marks and the like related to the Omnicell
Products owned or controlled by Omnicell or its affiliated companies, in each
case subject to the prior written consent of Omnicell as to the form and content
of such use.

     7.2 During the Term of this Agreement, Omnicell may use, only in connection
with Omnicell's marketing and promotion of the Bergen products and services,
trademarks, insignias, logos, proprietary marks and the like related to the
Bergen products and services owned or controlled by Bergen or its affiliated
companies, in each case, subject to the prior written consent of Bergen as to
the form and content of such use.

8. CONFIDENTIAL INFORMATION AND OTHER MATTERS.

     8.1 Bergen acknowledges that it may acquire and develop certain non-public
knowledge, information and material concerning Omnicell, its business,
customers, products and services which are and shall be the trade secrets and
confidential and proprietary information of Omnicell (the "Omnicell Confidential
Information"). Bergen shall hold such Omnicell Confidential Information in
strict confidence and, except for disclosure to Bergen employees so long as such
disclosure is necessary for Bergen in the exercise of its rights hereunder, not
disclose it to others, not use it in any way or permit others to use it in any
way, commercially or otherwise, and not allow any unauthorized person, firm or
corporation access to such Omnicell Confidential Information either before or
after termination of this Agreement, without the prior written consent of
Omnicell or unless the third party is an end-user or customer who agrees to
abide by a confidentiality agreement which has the effect of protecting
Omnicell's rights and interests in the Omnicell Products to the extent set forth
herein.

     8.2 Omnicell acknowledges that it may acquire and develop certain
non-public knowledge, information and material concerning Bergen, its affiliated
companies and their respective businesses, customers, products and services
which are and shall be the trade

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       5

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

secrets and confidential and proprietary information of Bergen or its affiliated
companies (hereinafter, the "Bergen Confidential Information"). Omnicell shall
hold such Bergen Confidential Information in strict confidence and, except for
disclosure to Omnicell employees so long as such disclosure is necessary for
Omnicell in the exercise of its obligations hereunder, not disclose it to
others, not use it in any way or permit others to use it in any way,
commercially or otherwise, and not allow any unauthorized person, firm or
corporation access to such Bergen Confidential Information either before or
after termination of this Agreement, without the prior written consent of Bergen
or unless the third party is an end-user or customer who agrees to abide by a
confidentiality agreement which has the effect of protecting Bergen's rights and
interests to the extent set forth herein.

     8.3 The Bergen Confidential Information and the Omnicell Confidential
Information shall hereinafter be collectively referred to as the "Confidential
Information." The Confidential Information shall not include information if (i)
as evidenced by written records, it was in the lawful possession of the
receiving party at the time of disclosure; (ii) at the time of disclosure, it is
in the public domain; (iii) after disclosure, it becomes, through no act or
omission on the part of the receiving party, in the public domain; or (iv) it
was lawfully and independently obtained from a third party who was not under
obligation of confidentiality to the disclosing party of any of its affiliates
either by law or under an express or implied agreement.

9. CERTAIN REMEDIES; INDEMNIFICATION.

     9.1 Bergen and Omnicell acknowledge and agree that the covenants and
agreements in Sections 8, 9 and 14 of this Agreement are made for the benefit of
the other and shall survive the termination of this Agreement for a period of
five (5) years. The parties acknowledge and agree that any breach by the other
of their respective covenants and agreements contained herein will result in
irreparable harm to the non-breaching party and that such party shall be
entitled to injunctive relief for such breach in addition to other relief to
which that party shall be entitled.

     9.2 Bergen shall indemnify, defend and hold harmless Omnicell, its
subsidiaries, affiliated or related companies, directors, officers, employees
and agents, against all losses, damages, expenses, judgments, costs and
reasonable attorneys' fees arising out of a breach of this Agreement by Bergen
or its employees or agents and any claims based on infringement by the Bergen
Software Platforms or any portion thereof of any patents, copyrights, trade
secrets, or other proprietary rights of another or arising in connection with
Bergen's obligations to a joint customer of Bergen and Omnicell pursuant to a
separate agreement between Bergen and such customer; provided Omnicell promptly
notifies Bergen of such a claim; allows Bergen to control the defense,
settlement and compromise of such a claim; and provides reasonable cooperation
to Bergen in the defense of such a claim.

     9.3 Omnicell shall indemnify, defend and hold harmless Bergen, its
subsidiaries, affiliated or related companies, directors, officers, employees
and agents, against all losses, damages, expenses, judgments, costs and
reasonable attorneys' fees arising out of a breach of this Agreement by Omnicell
or its employees or agents and any claims based on infringement by the Omnicell
Products or the Omnicell Software Platforms, or any portion thereof, of any
patents, copyrights, trade secrets, or other proprietary rights of another or
arising in connection with Omnicell's obligations to a joint customer of Bergen
and Omnicell pursuant to a separate agreement between Omnicell and such customer
or based upon the

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       6

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

performance of Omnicell Products; provided Bergen promptly notifies Omnicell of
such a claim; allows Omnicell to control the defense, settlement and compromise
of such a claim; and provides reasonable cooperation to Omnicell in the defense
of such a claim.

     9.4 In addition to the foregoing, Omnicell shall indemnify Bergen for those
additional matters set forth in Schedule C.

     9.5 In connection with any claim or action brought by either party as a
result of or pursuant to the terms of this Agreement, both of these parties
agree that in no event shall either party be liable to the other party for any
consequential, special, punitive, exemplary, indirect or incidental damages
(including but not limited to loss of anticipated profits, loss of use, or loss
of product), whether or not foreseeable and irrespective of the theory or cause
of action upon which such damages might be based, including but not limited to
negligence or other tort, contract, strict liability, breach of warranty, or
otherwise.

10. RELATIONSHIP OF PARTIES.

     This Agreement does not in any way create the relationship of joint
venture, partnership or principal and agent between Omnicell and Bergen. Each
party is an independent contractor, and as such, shall not act or represent
itself, directly or indirectly or by implication, as agent for the other or
assume or create any obligation on behalf of or in the name of the other, or
otherwise bind the other in any manner. Without limiting the generality of the
foregoing, Bergen, nor its agents or employees, shall not have the authority to
accept orders for the Omnicell Products binding upon Omnicell or otherwise enter
into binding agreements of any nature whatsoever on behalf of Omnicell, without
the prior consent of Omnicell.

11. NON-COMPETE.

     During the Term of this Agreement, Bergen shall not compete with Omnicell
by entering into the automation dispensing markets and Omnicell will not compete
with Bergen by entering into the drug distribution market. If either party or an
affiliated company of that party is acquired by a competitor of the non-acquired
party, then in such event, the non-acquired party shall be entitled to terminate
this Agreement immediately and without penalty. For purposes of this Agreement,
an "affiliate" or an "affiliated company" means, with respect to a party, any
entity that, directly or indirectly, or through one or more intermediaries, owns
or controls, is owned or controlled by, or is under common ownership or common
control with, that party. Likewise, "control" means either owning, directly or
indirectly, at least 51% of the voting stock or interests of a party (on a
fully-diluted basis) or having the ability, directly or indirectly, to elect a
majority of the board of directors or other governing members of a party.

12. COMPLIANCE WITH LAWS.

     Each party shall perform its obligations in compliance with all laws,
regulations, ordinances and orders ("Laws") of any applicable governmental
entity having jurisdiction over such party. Neither party shall be obligated to
perform any of the obligations contemplated by this Agreement to the extent
that, in the opinion of legal counsel to such party, doing so would violate any
Laws.

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       7

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

13. DISPUTE RESOLUTION.

     In the event a dispute arises between the parties hereunder in respect of
how a service issue related to a joint customer should be resolved, either party
may submit to a local office of the American Arbitration Association a request
for mediation, whereupon each party will be obligated to proceed promptly in
good faith towards submitting the issue to a mediator for final and binding
resolution.

14. MISCELLANEOUS.

     14.1 GOVERNING LAW. This Agreement shall be governed by, interpreted and
construed in accordance with the laws of the State of California without regard
to its choice of law provisions. The parties to this Agreement each hereby
irrevocably submit to the jurisdiction of the Superior Court of the County of
Orange, California, or the United States District Court for the Central District
of California for the purpose of any suit, action, or other proceeding arising
out of this Agreement.

     14.2 ENTIRE AGREEMENT. This Agreement contains the entire agreement between
the parties with respect to the matters covered herein and may not be amended,
altered or modified except in writing, signed and agreed to by an authorized
representative of each party.

     14.3 COUNTERPARTS. This Agreement may be executed in several counterparts,
each of which shall be deemed an original, and such counterparts shall together
constitute but one and the same Agreement, binding upon the parties hereto.

     14.4 NO WAIVER. The failure of a party at any time to enforce any
provisions of this Agreement shall not be construed as a waiver of any provision
of this Agreement, or of the right of such party thereafter to enforce each and
every provision of this Agreement.

     14.5 ATTORNEYS FEES. In the event that any dispute between the parties
under this Agreement should result in any suit, action, or other proceeding,
then the prevailing party shall be entitled to recover from the other party all
reasonable fees, costs and expenses (including reasonable attorneys fees)
incurred in connection with such suit, action or proceeding.

     14.6 NOTICES. Any notice, request, demand or other communication required
or permitted under the terms of this Agreement must be in writing and must be
delivered personally or sent by a nationwide overnight air courier service
(prepaid, receipt acknowledgement requested), or by registered or certified mail
(postage prepaid, return receipt requested), addressed as shown below:

               Notices to Bergen should be sent to:

               Bergen Brunswig Drug Company
               Attn:  President
               4000 Metropolitan Drive
               Orange, California  92868

               With a copy to:

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       8

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

               Bergen Brunswig Corporation
               Attn:  Chief Legal Officer
               4000 Metropolitan Drive
               Orange, California  92868

               Notices to Omnicell should be sent to:

               Omnicell
               Attn:  Chief Financial Officer
               1101 East Meadow Drive
               Palo Alto, CA  94303

               With a copy to:

               Omnicell
               Attn:  Corporate Counsel
               1101 East Meadow Drive
               Palo Alto, CA  94303

     14.7 SEVERABILITY. If any provision or the scope of any provision of this
Agreement is found to be unenforceable or too broad in any respect pursuant to
any judicial decree or decision to permit enforcement to its full extent, such
provisions shall then be enforced to the maximum extent permitted by law, and
the parties consent and agree that such provisions shall be curtailed only to
the extent necessary to conform to law.

     14.8 ASSIGNMENT. Neither party may assign this Agreement without the prior
written consent of the other party (such consent not to be unreasonably
withheld), except to an affiliated entity. For purposes of this Section, any
transfer, sale, merger or consolidation of a party, or the sale of a substantial
portion of such party's assets, whether by contract, agreement, operation of
law, or any other transaction or series of related transactions transferring all
or substantially all of the party's business, assets (including this Agreement),
stock, or control shall be deemed an assignment and require the prior written
consent of the other party, but shall not modify, supplement, or terminate the
rights or obligations of the parties hereunder. Omnicell acknowledges that
Bergen Brunswig Corporation and AmeriSource Health Corporation have entered into
that certain Agreement and Plan of Merger dated March 16, 2001 (the "AmeriSource
Bergen Merger Agreement"), and for purposes of this provision Omnicell hereby
gives its consent for the assignment that may be deemed to occur upon
consummation of the transactions contemplated by such merger agreement. Bergen
acknowledges that Omnicell intends to make an initial public offering of its
common stock pursuant to its registration statement on file with the SEC and to
reincorporate in Delaware, and for purposes of this provision Bergen hereby
gives its consent for the assignment that may be deemed to occur upon
consummation of the transactions contemplated by such offering and
reincorporation. This Agreement shall be binding upon the parties hereto and
their successors, heirs and assigns, as permitted.

     14.9 FORCE MAJEURE. No Party shall be responsible or considered in breach
of this Agreement for any delay or failure in the performance of any obligation
of this Agreement to the extent that such failure or delay is caused by acts of
God, fires, explosions, labor disputes, accidents, civil disturbances, material
shortages or other similar causes beyond its

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       9

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

reasonable control, even if such delay or failure is foreseeable; provided,
however, that the non-performing Party provides notice of such cause preventing
or delaying performance and resumes its performance as soon as practicable and
provided further that the other parties may terminate this Agreement upon notice
if such non-performance continues for a period of ninety (90) days.

     14.10 USE OF NAME. Neither Party hereto shall use the name of the other
Party in any third party or public disclosure, including without limitation any
advertising, offering materials, prospectus or filings with any governmental
entity without prior written approval of such Party, such approval not to be
unreasonably withheld.

     14.11 CONFIDENTIAL TREATMENT. In the event a Party is required in the
opinion of counsel to file this Agreement as part of or in connection with a
filing made with the Securities and Exchange Commission, such Party shall seek
confidential treatment of the information set forth in Schedule A, Schedule B
and Schedule C.

     IN WITNESS WHEREOF, the parties hereto have signed this Agreement as of the
date first above written.

<TABLE>
<S>                                                           <C>
OMNICELL.COM, a California corporation                        BERGEN BRUNSWIG DRUG COMPANY, a California corporation

By:                                                           By:
   --------------------------------------------------            --------------------------------------------------

Name:                                                         Name:
     ------------------------------------------------              ------------------------------------------------

Its:                                                          Its:
    -------------------------------------------------             -------------------------------------------------

Date:                                                         Date:
     ------------------------------------------------              ------------------------------------------------
</TABLE>

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       10

<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

                                   SCHEDULE A

         1. Omnicell shall not enter into either [*] or [*] as it will have
with Bergen with [*] during the Term of the Agreement and represents to
Bergen that it has not entered into a [*] with [*] prior to the Term of this
Agreement.

         2. Omnicell may work with [*] for the sales of [*] in certain [*];
provided, however, Omnicell shall be [*] in connection with [*] to or from [*]
or enter into a relationship where the [*] could claim a preferred status
with Omnicell. Notwithstanding the foregoing, [*] may be permitted to include
Omnicell Products in any RFP responses where [*] have not been requested.

         3. Bergen shall not enter into either [*] or [*] as it will have
with Omnicell with [*] during the Term of the Agreement and represents to
Omnicell that it has not entered into a [*] with any other of the [*] prior
to the Term of this Agreement.

         4. Bergen may work with the [*] for the sales of [*] in certain [*];
provided, however, Bergen shall be [*] in connection with [*] to a [*] or
enter into a relationship where the [*] could claim a preferred status with
Bergen. Notwithstanding the foregoing, the [*] may be permitted to include
Bergen products in any RFP responses where [*] have not been requested.

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       11
<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

                                   SCHEDULE B

         1. In the event Bergen acquires Omnicell shares of stock in the
initial public offering or otherwise makes an "Investment" pursuant to
paragraph 6 below, Omnicell, at such time, shall begin to pay to Bergen a
commission of [*] derived from pharmacy automation products ("Commission") at
accounts as defined in paragraph 1. Commissions are due to Bergen from
Omnicell under the following circumstances:

         (a)  where the account is not then currently a customer of Bergen (as
              primary drug distributor) nor Omnicell, and selects Omnicell
              Product and Bergen (as primary drug distributor) as a result of a
              joint RFP response or joint marketing presentation by Omnicell and
              Bergen where the collaborative relationship has been presented to
              the account;

         (b)  where Bergen is the then current primary drug distributor and
              Omnicell is not an existing supplier of the Omnicell Product and
              the account selects Omnicell Product as a result of a joint RFP
              response or joint marketing presentation by Omnicell and Bergen
              where the collaborative relationship has been presented to the
              account;

         (c)  where the account is not then currently a Bergen customer (as
              primary drug distributor) but is then currently an Omnicell
              customer and expands its Omnicell Product implementation and
              selects Bergen as the primary drug distributor as a result of a
              joint RFP response of joint marketing presentation by Omnicell and
              Bergen where the collaborative relationship has been presented to
              the account;

         (d)  where the account is then currently a customer of each Bergen (as
              primary drug distributor) and Omnicell and expands its Omnicell
              Product implementation, but only in the event its primary drug
              distribution agreement with Bergen is modified, extended or
              otherwise revised to enhance or substantially benefit the
              collaborative relationship, as a result of a joint RFP response or
              joint marketing presentation where the collaborative relationship
              has been presented to the account; and

         (e)  where the account at any time during the Term has previously
              satisfied any of the conditions in any of (a) - (d) above,
              continues or initiates business with Bergen as its primary drug
              distributor and expands its Omnicell Product implementation.

The Commission called for by this paragraph 1 will be paid so long as the sale
occurs at any time while (i) this Agreement remains in full force and effect
between the parties and within six (6) months after termination of this
Agreement for any reason; and (ii) the agreement between Bergen and the account
remains in full force and effect or within six (6) months after termination of
such agreement. In the event the parties wish to enter into a similar
arrangement with respect to commissions for OmniBuyer(TM) (or successor system),
those commissions shall be subject to a separate written agreement as may be
negotiated between the parties. In the event Bergen does not acquire Omnicell
shares of stock in the

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       12
<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

IPO or otherwise make an Investment, Omnicell will not be required to pay to
Bergen any Commissions hereunder.

         2. Omnicell's cash payment of Commissions to Bergen shall occur by the
end of the month following the month in which Omnicell receives payment from the
applicable customer.

         3. Omnicell shall provide a monthly accounting to Bergen for all sales
of Omnicell pharmacy automation products that meet any of the thresholds
detailed in paragraph 1 above. All sums payable hereunder shall be paid without
notice, demand set off or deduction.

         4. The parties hereto shall have the right on thirty (30) days written
notice to the other party, to audit each other's books and records relating to
the accounting of Revenues or for any other purpose reasonably related to the
other party's obligations under this Agreement, provided that such audits shall
occur no more than twice in any calendar year and shall take place at the
offices of the auditee at the expense of the auditor, during normal business
hours.

         5. In connection with any initial public offering ("IPO") of shares of
capital stock of Omnicell, Omnicell agrees to reserve for offer to Bergen shares
of such stock at the initial offering price for such shares with an aggregate
value equivalent to Five Million Dollars ($5,000,000), provided that such shares
have been registered with the U.S. Securities and Exchange Commission (the
"SEC") pursuant to an appropriate registration statement under the Securities
Act of 1933, as amended, which registration statement will have been declared
effective by the SEC, and provided further that such IPO occurs on or before
December 31, 2001. Except in connection with any required pledge of collateral
pursuant to any financing agreements previously entered into between Bergen's
parent corporation and any third party, and except in connection with any
successor entity restructuring subsequent to the merger contemplated by the
AmeriSource Bergen Merger Agreement, Bergen shall not assign, transfer, sell,
pledge, hypothecate or otherwise dispose of such shares for a period of one (1)
year from the date of the IPO; provided, however, in the event of a Change in
Control (as defined hereinafter) of Omnicell during such one (1) year period of
restriction, such restriction shall automatically terminate and Bergen shall
have the right to make any disposition of the shares as it deems appropriate in
its sole discretion. For purposes of the foregoing, "Change in Control" shall
mean (i) any change in the ownership or effective control of Omnicell, or (ii)
any change in the ownership of a substantial portion of the assets of Omnicell;
all within the meaning of Section 280G of the Internal Revenue Code of 1986, as
amended to date, or any successors provision thereto, regulations (including
temporary and proposed regulations) promulgated thereunder, and judicial
interpretations of Section 280G and the regulations.

         6. In the event that the IPO is not consummated, prior to December 31,
2001 Bergen will have the option, but not the obligation, to make an investment
ranging between Three Million Dollars ($3,000,000) and Five Million Dollars
($5,000,000) in Omnicell, on such terms as may be mutually agreeable to the
parties and memorialized by written instruments (the "Investment").

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       13
<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE
SECURITIES ACT OF 1933, AS AMENDED.

                                   SCHEDULE C

         Omnicell shall indemnify, defend and hold harmless Bergen, its
subsidiaries, affiliated or related companies, directors, officers, employees
and agents, against all losses, damages, expenses, judgments, costs and
reasonable attorneys' fees arising out of any third party claims alleging a
material misstatement or omission in the information contained in any
registration statements filed with the SEC or any other public dissemination of
information by Omnicell, describing the relationship between Bergen and
Omnicell, including without limitation, information regarding Omnicell's
business prospects, financial results, source of funds, results of operations or
business relationships; provided Bergen promptly notifies Omnicell of such a
claim; allows Omnicell to control the defense, settlement and compromise of such
a claim; and provides reasonable cooperation to Omnicell in the defense of such
a claim. The parties agree that the survival provisions and limitations on
liability set forth in Article 9 of the Agreement shall apply to claims for
indemnification pursuant to this Schedule C.

[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

                                       14Prepared by MERRILL CORPORATION

QuickLinks
 -- Click here to rapidly navigate through this document

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 
 

Exhibit 10.39    
  

    LICENSE AND COMMERCIALIZATION AGREEMENT  

 BY AND BETWEEN  

 AMGEN INC.  

 AND  

 INTERMUNE, INC.  

June 15, 2001  

   TABLE OF CONTENTS  

	 
	 	 
	 	Page

	ARTICLE 1	 	DEFINITIONS	 	1
	 	1.1	 	"Active Component"	 	1
	 	1.2	 	"Affiliate"	 	1
	 	1.3	 	"Amgen Know-How"	 	1
	 	1.4	 	"Amgen Trademarks"	 	1
	 	1.5	 	"Amgen Patent"	 	2
	 	1.6	 	"Amgen Technology"	 	2
	 	1.7	 	"BLA"	 	2
	 	1.8	 	"CMC"	 	2
	 	1.9	 	"Combination Product"	 	2
	 	1.10	 	"Commercialize" or "Commercialization"	 	2
	 	1.11	 	"Commercially Reasonable Efforts"	 	2
	 	1.12	 	"Confidential Information"	 	2
	 	1.13	 	"Control"	 	2
	 	1.14	 	"Default"	 	2
	 	1.15	 	"Directly Competitive Product"	 	2
	 	1.16	 	"Dollar"	 	2
	 	1.17	 	"Drug Approval Application"	 	2
	 	1.18	 	"Existing License"	 	3
	 	1.19	 	"Existing License Patents"	 	3
	 	1.20	 	"Existing Licensor"	 	3
	 	1.21	 	"FDA"	 	3
	 	1.22	 	"Force Majeure"	 	3
	 	1.23	 	"GAAP"	 	3
	 	1.24	 	"Infergen"	 	3
	 	1.25	 	"IND"	 	3
	 	1.26	 	"Interferon alfacon-1"	 	3
	 	1.27	 	"Licensed Product"	 	3
	 	1.28	 	"Losses"	 	3
	 	1.29	 	"Net Sales"	 	3
	 	1.30	 	"Ongoing Clinical Trials"	 	3
	 	1.31	 	"Other Licensee"	 	3
	 	1.32	 	"Patent"	 	3
	 	1.33	 	"PEG Know-How"	 	4
	 	1.34	 	"PEG Patent"	 	4
	 	1.35	 	"PEG Program"	 	4
	 	1.36	 	"PEG-Infergen Product"	 	4
	 	1.37	 	"Phase III Clinical Trial"	 	4
	 	1.38	 	"Phase IV Clinical Trial"	 	4
	 	1.39	 	"Planning Period Date"	 	4
	 	1.40	 	"Regulatory Approval"	 	4
	 	1.41	 	"Regulatory Authority"	 	4
	 	1.42	 	"Royalty" or Royalties"	 	4
	 	1.43	 	"Sublicensee"	 	4
	 	1.44	 	"Supply Terms"	 	4
	1.45	 	"Term"	 	4
	 	1.46	 	"Territory"	 	4
	 	1.47	 	"Third Party"	 	4
	 	1.48	 	"Trademark"	 	4
	 	1.49	 	"Valid Claim"	 	5
	ARTICLE 2	 	LICENSES; EXCLUSIVITY; TRADEMARKS	 	5
	 	2.1	 	Technology Ownership	 	5
	 	2.2	 	Patent License to InterMune	 	5
	 	2.3	 	Trademark and Copyright Licenses to InterMune	 	5
	 	2.4	 	Know-How License to InterMune	 	5
	 	2.5	 	Sublicenses	 	5
	 	2.6	 	Sublicensed Technology	 	6

i

 

	 	2.7	 	Exclusivity	 	7
	 	2.8	 	Retained Rights.	 	7
	 	2.9	 	Import	 	7
	 	2.10	 	Covenant.	 	7
	ARTICLE 3	 	DEVELOPMENT	 	7
	 	3.1	 	Ongoing Clinical Trials.	 	7
	 	3.2	 	PEG—Infergen Products	 	7
	 	3.3	 	Development Efforts.	 	8
	 	3.4	 	Amgen Interim Activities.	 	8
	 	3.5	 	Development Data.	 	8
	 	3.6	 	Development Activities in Territory.	 	8
	ARTICLE 4	 	REGULATORY	 	8
	 	4.1	 	General	 	8
	 	4.2	 	Additional Regulatory Filings	 	9
	 	4.3	 	InterMune Access to Amgen Regulatory Data	 	9
	 	4.4	 	Adverse Event Reporting; Customer Complaints	 	9
	 	4.5	 	Communications	 	10
	 	4.6	 	Applications for Regulatory Exclusivity	 	10
	 	4.7	 	Recalls and Voluntary Withdrawals.	 	10
	 	4.8	 	Safety and Clinical Database	 	10
	ARTICLE 5	 	COMMERCIALIZATION	 	11
	 	5.1	 	Pricing	 	11
	 	5.2	 	Diligence	 	11
	 	5.3	 	Reports	 	11
	 	5.4	 	Amgen Transition Assistance	 	11
	 	5.5	 	Change of Promotional Material	 	11
	 	5.6	 	Medical and Other Inquiries	 	11
	 	5.7	 	Trade Returns; Reimbursements	 	12
	 	5.8	 	Distribution Agreements	 	12
	ARTICLE 6	 	COMPENSATION	 	13
	 	6.1	 	License Fee	 	13
	 	6.2	 	Amgen Performance Milestones.	 	13
	 	6.3	 	Product Milestones	 	13
	 	6.4	 	Royalties	 	14
	 	6.5	 	Term of Royalties	 	14
	 	6.6	 	Combination Products	 	14
	 	6.7	 	Existing License Royalties	 	14
	 	6.8	 	Royalty Payments and Reports	 	15
	 	6.9	 	Taxes	 	15
	 	6.10	 	Blocked Currency	 	15
	 	6.11	 	Foreign Exchange	 	15
	 	6.12	 	Patent and Trademark Expenses	 	15
	 	6.13	 	Late Payments	 	15
	ARTICLE 7	 	MANUFACTURE AND SUPPLY	 	16
	 	7.1	 	General.	 	16
	ARTICLE 8	 	INTELLECTUAL PROPERTY	 	16
	 	8.1	 	Ownership of Inventions	 	16
	 	8.2	 	Prosecution of Patents	 	16
	 	8.3	 	Infringement of Patents and Trademarks by Third Parties	 	16
	 	8.4	 	Infringement of Third Party Rights	 	17
	 	8.5	 	Patent Marketing	 	17
	ARTICLE 9	 	REPRESENTATIONS AND WARRANTIES	 	18
	 	9.1	 	Mutual Representations and Warranties	 	18
	 	9.2	 	Mutual Covenants	 	18
	 	9.3	 	Representations, Warranties and Covenants of InterMune	 	18
	 	9.4	 	Representations, Warranties and Covenants of Amgen	 	19
	ARTICLE 10	 	 	 	20
	 	10.1	 	Indemnification by Amgen	 	20
	 	10.2	 	Indemnification by InterMune	 	20
	 	10.3	 	Insurance	 	20

ii

 

	 	10.4	 	Pre-Effective Date Losses.	 	21
	 	10.5	 	Limitation of Liability	 	21
	ARTICLE 11	 	RECORDS; ROYALTY AUDIT; PUBLICATIONS	 	21
	 	11.1	 	Records; Royalty Audit	 	21
	 	11.2	 	Publications	 	21
	ARTICLE 12	 	CONFIDENTIALITY	 	22
	 	12.1	 	Treatment of Confidential Information	 	22
	 	12.2	 	Authorized Disclosure	 	22
	 	12.3	 	Publicity; Terms of Agreement	 	22
	ARTICLE 13	 	TERM AND TERMINATION	 	23
	 	13.1	 	Term	 	23
	 	13.2	 	Discontinuation of Commercialization or Further Development	 	23
	 	13.3	 	Termination for Default	 	23
	 	13.4	 	Licenses Upon Expiration	 	23
	 	13.5	 	Survival	 	24
	 	13.6	 	Determination of PEG Diligence.	 	24
	ARTICLE 14	 	DISPUTE RESOLUTION	 	24
	 	14.1	 	Disputes	 	24
	 	14.2	 	Governing Law; Judicial Resolution	 	24
	 	14.3	 	Patent and Trademark Dispute Resolution	 	25
	ARTICLE 15	 	MISCELLANEOUS	 	25
	 	15.1	 	Entire Agreement; Amendment	 	25
	 	15.2	 	Force Majeure	 	25
	 	15.3	 	Notices	 	25
	 	15.4	 	Maintenance of Records	 	26
	 	15.5	 	No Strict Construction	 	26
	 	15.6	 	Assignment	 	26
	 	15.7	 	Performance by Affiliates	 	26
	 	15.8	 	Counterparts	 	26
	 	15.9	 	Severability	 	26
	 	15.10	 	Headings	 	27
	 	15.11	 	Further Actions	 	27
	 	15.12	 	Independent Contractors	 	27
	 	15.13	 	Use of Name	 	27
	 	15.14	 	No Waiver	 	27

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

iii

   LICENSE AND COMMERCIALIZATION AGREEMENT  

    This License and Commercialization Agreement (the "Agreement") is made effective as of the 15th day of June,
2001 (the "Effective Date") by and between Amgen Inc., a Delaware corporation having its principal place of business at One Amgen Center Drive,
Thousand Oaks, CA 91320-1799 ("Amgen") and InterMune, Inc., a Delaware corporation having its principal place of business at 1710
Gilbreth Road, Suite 310, Burlingame, CA 94010-1317 ("InterMune"). Amgen and InterMune are sometimes referred to herein individually as a "Party" and collectively as the "Parties", and
references to "InterMune" and "Amgen" shall include their respective Affiliates. 

Recitals  

    Whereas, Amgen has bioengineered, developed, obtained regulatory approval for, and currently markets in the
United States and Canada a pharmaceutical composition containing a novel, non-naturally occurring Type 1 interferon, sold under the trademark Infergen®; 

    Whereas, InterMune has clinically developed and currently markets an interferon-gamma product in the United States, and therefore has
both clinical development experience and a sales force that may be particularly well suited to market and further develop a product such as Infergen; 

    Whereas, InterMune desires to obtain, and Amgen wishes to grant InterMune, the exclusive license to commercialize and further develop
Infergen in the United States and Canada on the terms and conditions set forth herein; and 

    Whereas, Amgen is willing to supply InterMune, and InterMune wishes to be supplied by Amgen, with quantities of Infergen (as such term
is defined below) on the Supply Terms (as defined below); 

    Now Therefore, based on the foregoing premises and the mutual covenants and obligations set forth below, the Parties agree as follows: 

ARTICLE 1

DEFINITIONS  

    The following terms shall have the following meanings as used in this Agreement: 

    1.1 "Active Component" shall mean any product other than the Licensed
Product which [*] therapeutic or prophylactic function when combined with the Licensed Product. 

    1.2 "Affiliate" shall mean, except as provided below, a Person that,
directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with Amgen or InterMune. For purposes of this definition, "control" shall mean the
possession, direct or indirect, of the power to cause the direction of the management and policies of a Person, whether through ownership of fifty percent (50%) or more of the voting securities of
such Person, by contract or otherwise. Affiliate [*] shall  [*]

    1.3 "Amgen Know-How" shall mean the following information:
(1) information disclosed in the BLA for Infergen as of the Effective Date, (2) information disclosed as of the Effective Date in any BLA supplements for Infergen, (3) all
Amgen-sponsored investigator-driven clinical trial results, and the results of the Ongoing Clinical Trials, (subject to any contractual confidentiality obligations of Amgen to Third Parties regarding
such results); (4) Infergen sales and marketing training materials; (5) any regulatory data which Amgen provides to InterMune pursuant to Section 4.3;
(6) [ * ]; (7) the safety and clinical database referenced in
Section 4.8; and (8) Formulating Know-How (as defined in Section 12.1 of Exhibit F). 

    1.4 "Amgen Trademarks" shall mean the registered trademarks listed at  Exhibit A, all trademark applications
listed at Exhibit A and all trademarks issuing from
such applications, together with any renewals, modifications or extensions thereto. 

1

 

    1.5 "Amgen Patent" shall mean  [*]

    1.6 "Amgen Technology" shall mean all Amgen Patents, Amgen
Know-How and Amgen Trademarks. 

    1.7 "BLA" shall mean a Biological License Application for Regulatory
Approval filed in the United States. 

    1.8 "CMC" shall mean the Chemistry Manufacturing Control section of a
BLA. 

    1.9 "Combination Product" shall have the meaning assigned such term
pursuant to Section 6.6. 

    1.10 "Commercialize" or "Commercialization" shall mean those activities
relating to the promotion, marketing and sale of Licensed Products and shall include without limitation, Phase IV Clinical Trials or equivalent clinical trials conducted following Regulatory Approval
to market a pharmaceutical product. 

    1.11 "Commercially Reasonable Efforts" shall mean the level of efforts
and resources required to Commercialize a Licensed Product in a sustained manner consistent with the efforts a similarly situated biopharmaceutical company would typically devote to a product of
similar market potential, profit potential or strategic value resulting from its own research efforts, based on conditions then prevailing. Commercially Reasonable Efforts shall be determined on a
country-by-country (each country including its territories) basis for a particular Licensed Product, and it is anticipated that the level of effort will change over time
reflecting changes in the status of the Licensed Product and the country (including its territories) involved. 

    1.12 "Confidential Information" shall mean all information received by
either Party from the other Party pursuant to this Agreement, other than that portion of such information or materials which: 

    (a) is publicly disclosed by the disclosing Party, either before or after it becomes known to the receiving Party; 

    (b) was known to the receiving Party, without obligation to keep it confidential, prior to when it was received from the
disclosing Party; 

    (c) is subsequently disclosed to the receiving Party by a Third Party lawfully in possession thereof without obligation
to keep it confidential; 

    (d) has been publicly disclosed other than by the disclosing Party and without breach of an obligation of
confidentiality with respect thereto; or 

    (e) has been independently developed by the receiving Party without the aid, application or use of Confidential
Information, as demonstrated by competent written proof. 

    1.13 "Control" shall mean possession of the ability to grant a license
or sublicense as provided for herein under such intellectual property right without violating the terms of any agreement or other arrangement with any Third Party. 

    1.14 "Default" shall mean with respect to either Party (i) that
any representation or warranty of such Party set forth herein shall have been untrue in any material respect when made or (ii) such Party, such Party's Affiliate or such Party's sublicensee
shall have failed to materially perform any material obligation set forth herein. 

    1.15 "Directly Competitive Product" shall mean any pharmaceutical
product that contains [*] or [*] of such  [*] and that [*]
with  [*] in [*] such Licensed Product  [*]

    1.16 "Dollar" shall mean a United States dollar, and "$" shall be
interpreted accordingly. 

    1.17 "Drug Approval Application" shall mean an application for
Regulatory Approval required before commercial sale or use of a Licensed Product as a drug or to treat a particular indication in a regulatory jurisdiction, including without limitation applications
to expand the label of an approved drug. 

2

 

    1.18 "Existing License" shall mean that certain Agreement between  [*]

    1.19 "Existing License Patents" shall mean the Patents under which Amgen
has a license pursuant to the Existing License, a copy of which has been provided to InterMune. 

    1.20 "Existing Licensor" shall mean  [*]

    1.21 "FDA" shall mean the United States Food and Drug Administration, or
any successor thereto. 

    1.22 "Force Majeure" shall mean any occurrence beyond the reasonable
control of a Party that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder, if such occurs by reason of any act of God, flood, fire, explosion,
breakdown of plant, earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion, acts of public enemies, blockage or embargo, or any injunction, law, order,
proclamation, regulation, ordinance, demand or requirement of any government or of any subdivision, authority or representative or any such government, inability to procure or use materials, labor,
equipment, transportation, or energy sufficient to meet manufacturing needs without the necessity of allocation, or any other cause whatsoever, whether similar or dissimilar to those above enumerated,
beyond the reasonable control of such Party, if and only if the Party affected shall have used reasonable efforts to avoid such occurrence and to remedy it promptly if it shall have occurred. 

    1.23 "GAAP"  shall mean United States generally accepted accounting
principles. 

    1.24 "Infergen" shall mean the product containing Interferon
alfacon-1 for which Amgen has obtained Regulatory Approval in each country of the Territory prior to the Effective Date, in either bulk or filled and finished form. 

    1.25 "IND" shall mean Investigational New Drug application. 

    1.26 "Interferon alfacon-1" shall mean the polypeptide
having the amino acid sequence which is set forth in Exhibit C. 

    1.27 "Licensed Product" shall mean any product comprising Interferon
alfacon-1 or [*] Licensed Products include but are not limited to Infergen. 

    1.28 "Losses" shall mean suits, claims, actions, demands, liabilities,
expenses and/or losses, including without limitation reasonable legal expenses and attorneys' fees. 

    1.29 "Net Sales" shall mean all revenues recognized in accordance with
GAAP from the sale or other disposition of Licensed Products by InterMune, its Affiliates or Sublicensee to a Third Party, less  [*]

    Amounts
received by InterMune, its Affiliates or Sublicensees for the sale of Licensed Products among InterMune, its Affiliates and Sublicensees for resale shall not be included in
the computation of Net Sales hereunder. Distributors of InterMune selling Licensed Products shall not be deemed to be Sublicensees of InterMune. 

    1.30 "Ongoing Clinical Trials" shall mean those clinical trials listed
at Exhibit E hereto, which are clinical trials of Infergen that Amgen is conducting in the Territory as of the Effective Date. For avoidance of doubt, Ongoing Clinical Trials shall exclude any
Amgen-sponsored investigator-driven clinical trials. Amgen represents that the Ongoing Clinical Trials are the only clinical trials of Infergen being conducted in the Territory by or on Amgen's behalf
as of the Effective Date. 

    1.31 "Other Licensee" shall mean any Third Party to which Amgen has
granted or grants a license and/or sublicense to develop or Commercialize a Licensed Product outside the Territory, including without limitation  [*]

    1.32 "Patent" shall mean (i) an issued, unexpired patent (with
the term "patent" being deemed to encompass, without limitation, an inventor's certificate) which has not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal
can be taken or has been taken within the 

3

 

required time period, including without limitation any substitution, extension, registration, confirmation, reissue, re-examination, renewal or any like filing thereof or (ii) a
pending application for a patent, including without limitation any provisional, converted provisional, continued prosecution application, continuation, divisional or
continuation-in-part thereof; any patents issuing therefrom; and any substitution, extension, registration, confirmation, reissue, reexamination, renewal or like filing
thereof. 

    1.33 "PEG Know-How" shall mean any of the following which is
conceived, reduced to practice, developed or employed by Amgen (solely or jointly with InterMune) [*] the PEG Program:
(i) techniques and data specifically relating to (but not necessarily solely to) the [*] of PEG-Infergen
Product, including, but not limited to, [*] and
(ii) [*] of PEG Infergen Product. For avoidance of doubt, PEG Know-How as it relates to manufacturing, shall
only include [*] PEG-Infergen Products, and shall not include  [*]

    1.34 "PEG Patent" shall mean  [*]

    1.35 "PEG Program" shall mean a program of collaborative development by
the Parties of a PEG-Infergen Product (if any such program is agreed to by the Parties pursuant to Section 3.2). 

    1.36 "PEG-Infergen Product" shall mean a pharmaceutical
composition containing as its active ingredient [*]

    1.37 "Phase III Clinical Trial" means a clinical trial (or set of
clinical trials) of a pharmaceutical product on sufficient numbers of patients which, if the defined end-points are met, are designed or intended to file for Regulatory Approval on the
basis thereof. 

    1.38 "Phase IV Clinical Trial" shall mean a pharmaceutical product
support clinical trial of a pharmaceutical product commenced after receipt of Regulatory Approval in the country where such trial is being conducted. 

    1.39 "Planning Period Date" shall have the meaning assigned such term
pursuant to Section 3.2. 

    1.40 "Regulatory Approval" shall mean any approvals (including
supplements, amendments, pre- and post-approvals and price approvals), licenses, registrations or authorizations of any national, supra-national regional, state or local
regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the distribution, use or sale of a Licensed Product in a regulatory jurisdiction. Regulatory
Approval shall not include any [*]

    1.41 "Regulatory Authority" shall mean the FDA or any counterpart of the
FDA outside the United States. 

    1.42 "Royalty" or Royalties" shall mean those amounts payable as
royalties by InterMune to Amgen pursuant to Sections 6.4 and 6.7(a) of this Agreement. 

    1.43 "Sublicensee" shall mean a sublicensee of InterMune under
InterMune's rights pursuant to Section 2.2, 2.3 and 2.4, the sublicense to whom is permitted pursuant to Section 2.5. 

    1.44 "Supply Terms" shall mean the terms and conditions set forth in
Exhibit F. 

    1.45 "Term" shall mean the term of this Agreement. 

    1.46 "Territory" shall mean the United States and Canada, and the
possessions and territories of each such country. 

    1.47 "Third Party" shall mean any entity other than Amgen or InterMune
or an Affiliate of either of them. 

    1.48 "Trademark" shall mean any trade name, service mark, logo or
trademark (whether or not registered) together with all goodwill associated therewith, and any renewals, extensions or modifications thereto. 

4

 

    1.49 "Valid Claim" shall mean (i) an unexpired claim of an issued
patent within the Amgen Patents that has not been found to be unpatentable, invalid or unenforceable by a court or other authority in the country of the patent, from which decision no appeal is taken
or can be taken; or (ii) a claim of a pending application within the Amgen Patents, which application claims a first priority no more than  [*] prior to the date upon which pendency is determined.

ARTICLE 2

LICENSES; EXCLUSIVITY; TRADEMARKS  

    2.1 Technology Ownership. Except for items (1) and
(2) listed in the definition of Amgen Know-How, Amgen shall retain sole right and interest, subject only to the licenses granted in Section 2.2, 2.3 and 2.4 of this
Agreement, to the Amgen Technology. 

    2.2 Patent License to InterMune.

    (a) Subject to the terms and conditions of this Agreement, Amgen hereby grants to InterMune an exclusive (even as to
Amgen) license, with the right to grant sublicenses (subject to InterMune's compliance with Section 2.5 of this Agreement), under the Amgen Patents to  [*] Licensed Products in the Territory.

    (b) Subject to the terms and conditions of this Agreement, Amgen hereby grants to InterMune an exclusive (even as to
Amgen) sublicense, without the right to grant sublicenses, under the Existing License Patents to [*] Infergen in the Territory.
Except as expressly set forth herein, Amgen does not grant InterMune any other rights with respect to the Existing License or to Existing License Patents. 

    (c) Subject to the terms and conditions of this Agreement, Amgen hereby grants to InterMune an exclusive license (even
as to Amgen), under the PEG Patent, to [*] pegylated Licensed Products. 

    (d) Subject to the terms and conditions of this Agreement, Amgen hereby grants to InterMune an exclusive  [*] license (even as to Amgen), under PEG Know-How and
Patents claiming PEG Know-How, to  [*] pegylated Licensed Products. 

    2.3 Trademark and Copyright Licenses to InterMune. 

    (a) Amgen hereby grants to InterMune an exclusive  [*] license, with the right to grant sublicenses (subject to InterMune's compliance with Section 2.5 of this
Agreement),
under the entire right, title and interest in and to the Amgen Trademarks, to use and display the Amgen Trademarks in connection with Licensed Products in the Territory. InterMune shall have the right
to select for and use and display with Licensed Products such Trademarks as it desires, consistent with any reasonable quality standards which Amgen may prescribe for use and display of the Amgen
Trademarks. 

    (b) Amgen hereby grants to InterMune an exclusive  [*] license under Amgen's entire right, title and interest in any copyrights in Infergen-specific promotional
materials existing
on or before the Effective Date, with the right to grant sublicenses (subject to InterMune's compliance with Section 2.5 of this Agreement), to reproduce, distribute copies of, prepare
derivative works of and publicly perform and display such promotional materials in connection with Licensed Products in the Territory. 

    2.4 Know-How License to InterMune. Subject to the terms and
conditions of this Agreement, Amgen grants InterMune a [*], exclusive license under the Amgen Know-How to use the
Amgen Know-How for the sole purposes of [*] Licensed Products in the Territory. 

    2.5 Sublicenses. Subject to Amgen's prior written approval in each
instance, InterMune may grant sublicenses to Third Parties under Sections 2.2, 2.3 and 2.4. Notwithstanding the sublicensing of all or part of InterMune's rights and obligations hereunder, InterMune
shall remain responsible for the full and complete performance of all of InterMune's obligations and duties under this Agreement. There shall be 

5

 

no presumption that Amgen will provide its approval for InterMune to grant a sublicense to any Third Party, however Amgen shall not unreasonably withhold its consent. 

    2.6 Sublicensed Technology. Amgen shall timely perform and discharge its
obligations under the Existing License during the Term and shall not permit any action to be taken or event to occur, in each case, within Amgen's reasonable control, which would give Existing
Licensor the right to terminate Existing License. InterMune agrees that the rights granted under this Agreement are subject to, and agrees to be bound by, all the terms and conditions required of
sublicensees under the Existing License. 

6

 
    2.7 Exclusivity.

    (a) Except as explicitly permitted pursuant to this Agreement, Amgen shall not use, develop, import, promote, sell, or
offer for sale Licensed Products for use within the Territory. 

    (b) Amgen shall not [*] a Directly Competitive
Product in the Territory, and shall not [*] take such actions during the Term; provided,
however, that the foregoing prohibition shall be subject to Amgen's rights pursuant to Section 13.6. 

    2.8 Retained Rights. Notwithstanding the exclusive license granted
InterMune pursuant to Section 2.2, Amgen retains the non-transferable, non-exclusive right under the Amgen Patents and Amgen Know-How to  [*]; provided,
however, that, except as authorized under Section 12.2(b)
Amgen shall not publish the [*], to the extent [*] of
the [*] in [*] nothing shall prohibit Amgen or its
Affiliates from fulfilling its obligations or exercising its rights in this Agreement or with regard to Licensed Products outside the Territory. 

    2.9 Import. The term "import" or "importing" whenever used in this
agreement shall not permit InterMune to conduct any activities outside the Territory outside the Territory regarding Licensed Product without the express written consent of the Other Licensees. 

    2.10 Covenant. Amgen hereby covenants that it and its Affiliates,
assignees, and licensees ("Covenantors") shall not sue InterMune, its Affiliates and Sublicensees for infringement of any Patent owned or Controlled by any Covenantor, or under which any Covenantor
has the right to sue infringers, in each case during the Term [*]

ARTICLE 3

DEVELOPMENT  

    3.1 Ongoing Clinical Trials. As of the Effective Date, Amgen is
conducting the Ongoing Clinical Trials in the Territory. As soon as is reasonably practical after the Effective date, Amgen will assign (to the extent assignable) and transfer its clinical trial
contracts covering the Ongoing Clinical Trials to
InterMune. Amgen shall make reasonable efforts to complete such assignments within [*] days after the Effective Date and
transfer to InterMune any data from the Ongoing Clinical Trials that Amgen possesses as of such date. To the extent that Amgen is still conducting the Ongoing Clinical Trials during such  [*] day
transition period, Amgen shall comply with all applicable laws and regulations, and regulations of the Regulatory
Authorities having jurisdiction in the Territory in Amgen's conduct of the Ongoing Clinical Trials, shall keep InterMune promptly informed of any inquiries of such Regulatory Authorities regarding the
Ongoing Clinical Trials, shall provide InterMune with drafts of all proposed correspondence with any such Regulatory Authority regarding any Ongoing Clinical Trial and permit InterMune to be present
at any meeting with such a Regulatory Authority regarding any Ongoing Clinical Trial. InterMune shall reimburse Amgen for all Ongoing Clinical Trial expenses incurred by Amgen after the Effective
Date. 

    3.2 PEG-Infergen Products. InterMune shall have a period of  [*] days to [*] and whether it desires to have Amgen
provide [*] (as defined in the Code of Federal Regulations, as may be amended from time to time) for the  [*] The Parties recognize that Amgen's expertise
with Infergen may be particularly applicable to the preclinical development of
any PEG-Infergen Product. Within [*] days after the end of such  [*] day period, if InterMune notifies Amgen in writing that InterMune wishes to negotiate
with Amgen what development activities
Amgen would carry out with respect to such PEG-Infergen Product and commercially reasonable terms upon which Amgen would carry out such  [*] then Amgen and InterMune shall negotiate in good faith such
activities and terms for a period of no less than  [*] The end of such [*] day period shall be referred to
as the "Planning Period Date". The Parties have agreed that such commercially reasonable terms for the development of PEG-Infergen would include (i) InterMune funding any such
development work by Amgen at a rate equal to [*] and (ii) all PEG Know How and Patents claiming PEG 

7

 

Know-How, which shall be included in the Amgen Technology and therefore subject to the licenses of Article 2 of this Agreement. 

    3.3 Development Efforts. Beginning reasonably promptly after  [*] InterMune shall commence using Commercially
Reasonable Efforts to develop and seek Regulatory Approval for (in due course) a
PEG-Infergen Product in the regulatory jurisdictions of the Territory. 

    3.4 Amgen Interim Activities. As InterMune evaluates the business
opportunity for PEG-Infergen Products, Amgen will undertake the following preparatory activities to enable InterMune to better evaluate the possibility of conducting a collaborative PEG
Program with Amgen: 

    (a) Amgen will [*] with a  [*] and provide InterMune with written notice of such accomplishment. 

    (b) Amgen will prepare and provide to InterMune a written  [*] work plan detailing activities [*] as part of a PEG
Program and associated anticipated schedules and costs. Any such plan shall include a description of actions (and associated timings and costs) for Amgen to develop and supply InterMune with
quantities of GMP-compliant PEG-Infergen sufficient to commence Phase I Clinical Trials thereof. Such a plan shall be referred to herein as a
"[*] Work Plan." 

    Amgen's
actions as permitted by this Section 3.4 shall not be deemed to bind InterMune to proceed with a PEG Program in collaboration with Amgen. 

    3.5 Development Data. [*] InterMune shall
provide Amgen with written summaries of all pre-clinical and clinical data generated by InterMune with respect to Infergen (such summaries, the "Development Summaries"). All such
Development Summaries shall be considered Confidential Information of InterMune and Amgen may share it with its Other Licensees under appropriate obligations of confidentiality and non-use
commensurate with those contained herein. Upon any Other Licensee's request, InterMune will [*] in such detail as shall be
reasonably necessary to allow [*] outside the Territory. 

    3.6 Development Activities in Territory.

    (a) InterMune may collaborate or consult with researchers and investigators and contract for pre-clinical
studies without regard to whether such research, investigators and studies are inside or outside of the Territory and without obtaining permission from any Other Licensee, but in no event will
InterMune conduct clinical trials with any Licensed Product outside the Territory without advance written consent from the Other Licensee in whose territory outside the Territory InterMune wishes to
conduct such clinical trials. 

    (b) Amgen and any Other Licensee may collaborate or consult with researchers and investigators and contract for
pre-clinical studies without regard to whether such research, investigators and studies are inside or outside of the Territory and without obtaining permission from InterMune, but in no
event will Amgen or any Other Licensee conduct clinical trials in the Territory with any Licensed Product without advance written consent from InterMune. 

ARTICLE 4

REGULATORY  

    4.1 General. As of the Effective Date, Amgen owns in its own name
Regulatory Approvals for Infergen in each country of the Territory. Exhibit D contains a complete list of such Regulatory Approvals existing as of the Effective Date. Subject to Amgen's rights
of reference as described below in Section 4.3 and Amgen's
other rights pursuant to such Section, Amgen hereby assigns to InterMune Amgen's entire right, title and interest in and to all Regulatory Approvals and Drug Approval Applications for Infergen in the
Territory to InterMune. [*] after the Effective Date, Amgen shall notify Regulatory Authorities in the Territory of, and as soon
as is reasonably practicable thereafter take all actions reasonably necessary to effect or evidence, the transfer of such Regulatory Approvals to InterMune. In light of such assignment 

8

 

and transfer during the time period when Amgen will be transitioning the Ongoing Clinical Trials to InterMune, the Parties will  [*] to make appropriate arrangements in accordance with law to allow for
Amgen continue to conduct the Ongoing Clinical Trials
under Amgen's IND until the transition of the Ongoing Clinical Trials to InterMune is complete. For the avoidance of doubt, the transfer of such Regulatory Approvals shall not be effective to transfer
to InterMune ownership of, [*] any manufacturing trade secret disclosed therein, including without limitation,  [*]

    4.2 Additional Regulatory Filings. InterMune shall have the exclusive
right to file, and will own in its own name, any additional Drug Approval Applications for Licensed Products in the Territory, including without limitation any filings relating to label expansions for
Infergen. 

    4.3 InterMune Access to Amgen Regulatory Data.

    (a) Regulatory Data as of the Effective Date. Amgen will, as soon as is
reasonably practicable after the Effective Date, provide InterMune originals of the BLA and Canadian equivalent for Infergen in the United States and Canada, respectively, and all supplements to
either of the foregoing; provided, however that Amgen shall be entitled to redact any trade secret information relating to products other than Licensed
Products and any manufacturing trade secrets proprietary to Amgen (other than the [*] for Infergen). Amgen has provided
InterMune with a list of correspondence between Amgen and the FDA regarding Infergen for the approximately two (2) years prior to the Effective Date and shall provide InterMune with reasonable
access to the correspondence referenced in such list, and to other correspondence between Amgen and Regulatory Authorities having jurisdiction in the Territory, upon the request of InterMune. 

    (b) Regulatory Data Generated After the Effective Date. During the Term,
Amgen will provide to InterMune all regulatory data owned or Controlled by Amgen regarding any Licensed Product and necessary for marketing or making regulatory filings for Licensed Products in the
Territory as it becomes available. Such data shall be data generated in the Ongoing Clinical Trials (including adverse events encountered in the Ongoing Clinical Trials). Except for the information
contained in the CMC section of Amgen's BLA filings for Infergen, Amgen shall have no obligation, for any reason or under any circumstance, to provide InterMune with any information regarding Amgen's
manufacturing facility or any information pertaining to the manufacture of Licensed Products (including, without limitation,  [*]). 

    (c) Amgen Use of Information. Amgen shall have the right to review, a
right of access, a right of reference and the right to use and incorporate all Amgen Know-How outside the Territory or to satisfy Amgen's obligations in the Territory hereunder or to any
Other Licensee [*] The Parties shall discuss, as soon as practicable after the Effective Date, the form in which the Parties
shall exchange information pursuant to this Section 4.3 and Section 4.4. 

    (d) Legally Required Access. Notwithstanding anything to the contrary in
this Agreement, InterMune shall have the right to receive from Amgen, and Amgen shall provide to InterMune, any regulatory data or information (including without limitation manufacturing information)
to which InterMune, as the holder of any Regulatory Approval in the Territory, is required by law, rule, regulation or a Regulatory Authority having jurisdiction in the Territory, is required to have
access, but shall only be entitled to use such regulatory data or information to the extent required by such law, rule, regulation or Regulatory Authority. 

    4.4 Adverse Event Reporting; Customer Complaints.

    (a) After the Effective Date, InterMune shall be responsible for the adverse experience and safety reporting for the
Licensed Product in compliance with the requirements of the U.S. Food, Drug and Cosmetic Act, 21 USC § 321 et seq. and the regulations promulgated thereunder and the equivalent regulations
in the Territory; provided that Amgen shall provide interim adverse experience and safety reporting services for Infergen on InterMune's behalf for a
period of [*] after the Effective Date. Amgen shall, as soon as practicable following of the Effective Date, provide InterMune
with a 

9

 

summary of the information relating to the investigation and reporting of adverse experiences regarding Infergen and all information submitted to Regulatory Authorities in Amgen's BLA for Infergen and
any BLA supplements relevant to the safe use of Infergen. If Amgen receives any customer complaints regarding the marketing or distribution of Infergen in the Territory more than  [*] after the Effective
Date, it shall promptly refer such complaint to InterMune for handling. 

    (b) To enable InterMune to satisfy its reporting obligations to the Regulatory Authorities having jurisdiction in the
Territory, Amgen shall require each of its Other Licensees to disclose to Amgen and to allow Amgen to disclose to InterMune all information relating to adverse events encountered by or on behalf of
such Other Licensee in connection with any Licensed Products. 

    (c) InterMune shall reasonably promptly disclose to Amgen, and permit Amgen to disclose to Other Licensees all
information relating to adverse events encountered by or on behalf of InterMune in connection with the Licensed Products. 

    4.5 Communications. Except as may be required by law, requested by
InterMune or any Regulatory Authority having jurisdiction in the Territory, and except as to issues regarding the manufacture of Licensed Products in the Territory, Amgen shall not communicate
regarding any Licensed Product with any Regulatory Authority having jurisdiction in the Territory unless requested to do so by InterMune. Amgen will keep InterMune informed of any such required
communications. Amgen will reasonably cooperate with InterMune to make any communications regarding manufacture of any Licensed Product by Amgen for supply to InterMune, with the Regulatory
Authorities having jurisdiction in the Territory; provided that Amgen shall have no obligation,  [*] to provide InterMune with any information regarding
 [*] (including, without limitation, [*]). For so long as
Amgen is supplying InterMune with Infergen hereunder, Amgen shall have the right to be present at all meetings and telephone calls with the Regulatory Authorities having jurisdiction in the Territory
at which [*] is to be discussed. 

    4.6 Applications for Regulatory Exclusivity. The Parties recognize that
exclusivity rights granted or provided for under regulatory laws of the countries of the Territory may be commercially significant to Licensed Products. To the extent permitted by law, InterMune shall
have the exclusive right (even as to Amgen) to file for, request and maintain any regulatory exclusivity rights for Licensed Products in the Territory, including without limitation regulatory
exclusivity rights based upon an orphan drug designation of a Licensed Product, and to conduct and prosecute any proceedings or actions to enforce such regulatory exclusivity rights, and Amgen shall
reasonably cooperate with InterMune in such actions at InterMune's expense. 

    4.7 Recalls and Voluntary Withdrawals. The Parties shall exchange their
internal standard operating procedures as to product recalls ("SOPs") reasonably promptly after the Effective Date. If either Party becomes aware of information about quantities of Licensed Product
supplied by Amgen to InterMune indicating that such quantities of Licensed Product may not conform to the specifications for such product then in effect pursuant to the Supply Terms, or that there are
potential adulteration, misbranding and/or other issues regarding safety or effectiveness, it shall promptly so notify the other Party. The Parties will meet to discuss such circumstances and to
consider appropriate courses of action, which courses of action with respect to each recall shall be consistent with the internal SOP of the Party having the right to control such recall pursuant to
this Section 4.7. InterMune shall have the right to control, and shall bear all costs associated with, a recall of the Licensed Product in the Territory. If  [*] shall [*]
 not to  [*] in the [*] shall have the  [*] at [*]
 As between Amgen and InterMune, Amgen shall
control, at its sole expense, all recalls of Licensed Product outside the Territory. InterMune and Amgen shall each maintain complete and accurate records of any recall it has the right to control
pursuant to this Section 4.7 for such periods as may be required by legal requirements, but in any event for no less than three (3) years. 

    4.8 Safety and Clinical Database. Within sixty (60) days after
the Effective Date, Amgen shall transfer to InterMune Amgen's safety and clinical database relating to Infergen and existing on the Effective Date. 

10

 
ARTICLE 5

COMMERCIALIZATION  

    5.1 Pricing. InterMune shall determine in its sole discretion the
pricing, discounting policy and other commercial terms relating to Licensed Products in the Territory. 

    5.2 Diligence.

    (a) InterMune shall use its Commercially Reasonable Efforts to Commercialize Infergen in the Territory during the Term. 

    (b) Beginning promptly after the receipt of Regulatory Approval for a first PEG-Infergen Product in each
country of the Territory, InterMune shall use its Commercially Reasonable Efforts to Commercialize a PEG-Infergen Product in such country. 

    5.3 Reports. InterMune shall provide Amgen with detailed written  [*] reports concerning its efforts regarding
development and Commercialization of the Licensed Products in the Territory. The
information contained in such reports shall be deemed to be InterMune's Confidential Information. InterMune shall, at Amgen's request, promptly meet with Amgen no less frequently than  [*] to discuss the
[*] reports and InterMune's progress
regarding development and Commercialization of the Licensed Products in the Territory. 

    5.4 Amgen Transition Assistance.

    (a) During the period commencing on the Effective Date and ending  [*] Amgen shall provide (i) reasonable assistance to InterMune in notifying Amgen's
distributors and customers as of the
Effective Date of InterMune's license to Commercialize and further develop the Licensed Product; and (ii) [*] on
InterMune's behalf. 

    (b) Until [*] after the Effective Date, Amgen
shall provide reasonable assistance to InterMune to enable it to assume its responsibilities pursuant to Section 5.6. 

    (c) For a period of up to [*] after the
Effective Date, Amgen shall provide InterMune, at mutually agreed times and locations, with reasonable access to and assistance from those of Amgen's Infergen marketing personnel, as of the Effective
Date, selected by Amgen to transition the marketing and sales force training knowledge and materials to InterMune. Such assistance would include, without limitation, meeting with InterMune's marketing
and sales personnel to educate them regarding Infergen and the existing marketing arrangements that Amgen had in place for Infergen as of the Effective Date. 

    5.5 Change of Promotional Material. Promptly after the Effective Date
and subject to applicable regulatory requirements and Regulatory Approvals, InterMune, at its own expense, shall prepare all advertising and promotional materials for any Licensed Product to identify
InterMune (or its distributors) as the marketer of the Licensed Product, in such form as InterMune shall determine. As soon as practicable after the Effective Date, InterMune, at its own expense,
shall make such changes in the package insert, Licensed Product labeling and packaging as may be required to reflect InterMune as the marketer of the Licensed Product, including making all required
filings in connection therewith including without limitation filings with the Regulatory Authorities having jurisdiction in the Territory. Promptly after the Effective Date, Amgen shall file with
Regulatory Authorities in the Territory a notice that InterMune is the marketer and distributor of the Licensed Product in the United States. To the extent that Regulatory Authorities in the Territory
request additional information or meetings regarding InterMune's responsibilities as marketer and distributor of the Licensed Product in the Territory, Amgen and InterMune shall cooperate with each
other, and coordinate a response. 

    5.6 Medical and Other Inquiries. On the Effective Date, InterMune shall
assume all responsibility for all correspondence and communication with physicians and other health care professionals and customers in the United States and any other countries in the Territory where
Amgen had this responsibility relating 

11

 

to the Licensed Product. InterMune shall keep such records and make such reports as shall be reasonably necessary to document such communications in compliance with all applicable regulatory
requirements. After the Effective Date, Amgen shall refer all questions relating to the Licensed Product raised by health care professionals and customers to InterMune for its response. 

    5.7 Trade Returns; Reimbursements. Amgen shall bear all costs and
expenses related to all returns, charge backs and rebates for units of Licensed Products sold in the Territory prior to or on the Effective Date. InterMune shall bear all costs and expenses related to
all returns, charge backs and rebates for units of Licensed Products sold after the Effective Date. [*] shall bear all costs and
expenses related to Medicaid reimbursements for the Licensed Product [*] [*] shall bear all costs and
expenses related to Medicaid reimbursements for the Licensed Product [*] If Amgen receives any  [*] it shall promptly refer such [*] to InterMune for
handling. If InterMune receives any [*] InterMune shall promptly refer such  [*] to Amgen for handling. 

    5.8 Distribution Agreements. Amgen has  [*] of all outstanding material contracts, agreements or arrangements between
Amgen and any Third Party in the Territory
(including government agencies, health
maintenance organizations and all other buyers of Licensed Product, other than wholesalers) relating to the sale of the Licensed Product (collectively, "Distribution Agreements"). On the Effective
Date, InterMune shall assume Amgen's obligations under the Distribution Agreements, to the extent such Distribution Agreements are assignable by their terms and to the extent (i) pertaining to
time periods subsequent to the Effective Date and (ii) not arising on or before the Effective Date. To the extent any Distribution Agreement is not freely assignable, Amgen shall use reasonable
efforts to seek the consent of the applicable Distributor(s) to assign such Distribution Agreement to InterMune and, if and when so assigned, InterMune shall assume Amgen's obligations under such
Distribution Agreement to the extent (i) pertaining to a time period subsequent to the date such Distribution Agreement is assigned to InterMune, and (ii) not arising on or before such
date. 

12

   ARTICLE 6

COMPENSATION  

    6.1 License Fee.

    (a) Prior to the Effective Date InterMune paid Amgen one million Dollars ($1,000,000) in consideration of exclusive
negotiations that led to the execution of this Agreement. 

    (b) Within five (5) business days after the Effective Date, InterMune shall pay Amgen a license fee of twenty
million Dollars ($20,000,000) in cash by wire transfer of immediately available funds into an account designated by Amgen. This license fee shall be nonrefundable and noncreditable against Royalties
due Amgen pursuant to Section 6.3 and any other fees, milestone payments or other payments due Amgen under this Agreement. 

    6.2 Amgen Performance Milestones.

    (a) Within [*] days after  [*] InterMune shall pay Amgen a performance milestone payment equal to  [*]

    (b) Within [*] days after the time Amgen
provides InterMune with written notice, in accordance with Section [*] that Amgen has  [*] that is [*]
InterMune shall pay Amgen a performance
milestone payment equal to [*]

    (c) Within [*] business days after the time
Amgen provides InterMune with a [*] to do pursuant to  [*] InterMune shall pay Amgen a performance milestone payment equal to  [*]

    6.3 Product Milestones. 

    (a) InterMune shall pay to Amgen milestone payments as set forth in this Section 6.3(a) within  [*] days after the first achievement of the corresponding
milestone for a PEG-Infergen Product that is pegylated  [*] (an "Amgen PEG-Infergen Product") that is  [*] to be [*]. No milestone payment shall be payable
more than once, no matter how many times achieved by a single [*] or multiple  [*] Such milestone payments shall be nonrefundable and noncreditable against
royalties payable pursuant to Sections 6.4
and 6.7, and any other fees, milestone payments or other payments due Amgen under this Agreement. 

	Milestone Event
	 	Milestone Payment Amount

	1.  [*]	 	[*]
	2.  [*]	 	[*]
	3.  [*]	 	[*]
	4.  [*]	 	[*]
	5.  [*]	 	[*]
	 	 	

	Total	 	[*]

    (b) InterMune shall pay to Amgen milestone payments as set forth in this Section 6.3(b) within  [*] days after the first achievement of the corresponding
milestone for an Amgen PEG-Infergen Product  [*] No milestone payment shall be payable more than once, no matter how many times achieved by a single  [*] or
multiple [*] Such milestone payments shall be
nonrefundable and 

13

 

noncreditable against Royalties payable pursuant to Sections 6.4 and 6.7, and any other fees, milestone payments or other payments due Amgen under this Agreement. 

	Milestone Event
	 	Milestone Payment Amount

	1.  [*]	 	[*]
	2.  [*]	 	[*]
	3.  [*]	 	[*]
	4.  [*]	 	[*]
	5.  [*]	 	[*]
	 	 	

	Total	 	[*]

    (c) [*] Milestone Payments. If any Milestone
Event [ * ] to Amgen hereunder of any previously listed Milestone Payment
described in Sections 6.3(a) or (b), respectively, with respect to such Licensed Product, then [*] all previously listed
Milestone Payments described in Sections 6.3(a) or (b) with respect to such Licensed Product [*]

    6.4 Royalties. Subject to the other terms and conditions of this
Agreement, InterMune shall pay Amgen a royalty equal to [*] percent  [*] (the "Royalty") of Net Sales of each Licensed Product sold during each calendar
quarter by InterMune and its Affiliates and
Sublicensees. For purposes of calculating such royalty, Net Sales of any Combination Product shall be determined as provided pursuant to Section 6.6. 

    6.5 Term of Royalties. Amgen's right to receive Royalties under
Section 6.4 shall expire, on a Licensed Product-by-Licensed Product basis, in each country of the Territory upon the  [*]

    6.6 Combination Products. Net Sales of any Licensed Product sold by or
on behalf of InterMune, its Affiliates and/or its Sublicensees as part of a product which consists of the Licensed Product in combination with one or more Active Components ("Combination Product"),
for purposes of determining the Royalty payable to Amgen under Section 6.4, shall be calculated as follows: 

    (a) In the event each of the Active Components and Licensed Product are sold separately, the Net Sales for the purpose
of determining Royalties on sales of the Combination Product shall be calculated by multiplying Net Sales of such Combination Product by the fraction A/(A+B) where A is the price to Third Parties of
the Licensed Product component of the Combination Product when sold separately, and B is the price to Third Party end users of the Active Component(s) of the Combination Product when sold separately. 

    (b) If, on a country-by-country basis, the Active Component(s) in the Combination Product are
not sold separately in such country, but the Licensed Product is sold separately in such country, Net Sales for the purpose of determining Royalties of the Combination Product shall be calculated by
multiplying Net Sales of such Combination Product by the fraction A/C where A is the price to Third Party end users of the Licensed Product when sold separately, and C is the price to Third Parties of
the Combination Product. If, on a country-by-country basis, the Licensed Product is not sold separately in such country, Net Sales for the purposes of determining royalties of
the Combination Product shall be D/(D+E), where D is the fair market value of the portion of the Combination Product that contains the Licensed Product and E is the fair market value of the portion of
the Combination Product containing the Active Component(s) included in such Combination Product, as such fair market values are determined in good faith by the Parties. 

    6.7 Existing License Royalties. 

    (a) Amgen is, as of the Effective Date, a party to the Existing License, and pursuant to the Existing License Amgen owes
the Existing Licensor a royalty of [*] percent [*] on
Net Sales of Infergen by Amgen and its sublicensees under its licenses pursuant to the Existing License. In addition 

14

 

to Royalties payable by InterMune pursuant to Section 6.4, InterMune shall pay to Amgen a royalty equal to [*] percent  [*] of Net Sales of Infergen
sold during each calendar quarter by InterMune and its Affiliates. Such obligation to pay Amgen a
royalty beyond that due pursuant to Section 6.4 shall expire upon the expiration or termination of Amgen's obligation to pay a royalty for Infergen pursuant to the Existing License in respect
of Net Sales of Infergen by InterMune and its Affiliates. Without limiting Amgen's obligations pursuant to Section 2.6, including its obligations thereunder with respect to the Existing
License, Amgen shall timely make all payments due to the Existing Licensor under the Existing License in respect of InterMune's and its Affiliates' Net Sales of Infergen. Amgen shall promptly notify
InterMune of any notice of default or breach that it receives in relation to the Existing License. If the Existing License terminates or expires in such a way that Amgen does not have a right to
sublicense under any intellectual property licensed under the Existing License that relates to Infergen, Amgen shall promptly notify InterMune. 

    6.8 Royalty Payments and Reports. All Royalties payable to Amgen under
this Agreement (including Royalties payable to Amgen under Section 6.6(a) in relation to the Existing License) shall be paid in Dollars within  [*] days of the end of each calendar quarter except as
otherwise specifically provided herein. Each payment of Royalties owing
to Amgen shall be accompanied by a statement [*] in performing such computations and in accordance with GAAP, on a
country-by-country basis, of the amount of gross sales of Licensed Products and Combination Products, an itemized calculation of Net Sales of each Licensed Product and
Combination Product during such quarter, showing any deductions provided for in Section 1.30 during such quarter, the amount of aggregate worldwide gross sales of Licensed Product and
Combination Product and Net Sales during such quarter and on a cumulative basis for the current year and the amount of Royalty due on Net Sales during such quarter. 

    6.9 Taxes. Amgen shall be responsible for any and all taxes levied on
account of amounts it receives under this Agreement. If InterMune is required by law, rule or regulation to withhold taxes from such types of payments due Amgen hereunder, InterMune will
(i) deduct those taxes from the remittable amount, (ii) pay the taxes to the proper taxing authority, and (iii) send original copies of all official receipts evidencing such tax
obligation together with written evidence of payment to Amgen within [*] following that payment. In the event of such
withholding, the Parties agree to confer regarding other reasonable, lawful measures to minimize such withholding. 

    6.10 Blocked Currency. In any country of the Territory where conversion
of the local currency is blocked and such currency cannot be removed from the country, InterMune shall make payments of any Royalties due hereunder in respect of Net Sales of Licensed Products in such
country in local currency by depositing such amount to an interest-bearing account in the name of Amgen, in a bank within such country designated by Amgen. 

    6.11 Foreign Exchange. For the purpose of computing the Net Sales for
Licensed Products sold in a currency other than Dollars, such currency shall be converted into Dollars at the average rate of exchange for buying funds as retrieved from the on-line
edition of the Wall Street Journal (at http://www.interactive.wsj.com) for the calendar quarter in which such Net Sales were made. 

    6.12 Patent and Trademark Expenses. InterMune shall reimburse Amgen's
costs (as documented by written invoices for legal services and receipts for filing and maintenance fees paid) to [*]  provided that Amgen shall obtain advance written consent
from InterMune (such consent not to be unreasonably withheld) in the event any such expenses
[*] In the event InterMune does not consent to reimburse Amgen for any aspect related to  [*] Amgen shall not be obligated to continue any of its activities
or to incur any further costs or expenses related to such
aspect. 

    6.13 Late Payments. Any amounts not paid by InterMune when due under
this Agreement shall be subject to interest from and including the date payment is due through and including the date upon which InterMune has made a wire transfer of immediately available funds into
an account designated by Amgen at a rate equal to the sum of [*] plus the annual prime rate or successive annual prime rates of
interest 

15

 

quoted in the Money Rates section of the on-line edition of the Wall Street Journal (at http://www.interactive.wsj.com) calculated daily on the basis of a 365-day year. 

ARTICLE 7

Manufacture and Supply  

    7.1 General. As of the Effective Date, Amgen has established
manufacturing arrangements for bulk Infergen and finished Infergen. During the Term, Amgen shall supply to InterMune, and InterMune shall purchase from Amgen, InterMune's requirements of Licensed
Products for Commercialization and any further clinical development of Infergen in the Territory during the Term, on the Supply Terms (set forth in Exhibit F). The Parties intend to be bound to
a supply relationship pursuant to the Supply Terms. Each Party hereby agrees that the Supply Terms are sufficient to govern such relationship and legally binding upon the Parties. 

ARTICLE 8

INTELLECTUAL PROPERTY  

    8.1 Ownership of Inventions. Each Party shall own any inventions made
solely by its employees or agents in their activities hereunder. Inventions hereunder made jointly by employees or agents of each Party ("Joint Inventions") shall be owned jointly by the parties.
Except to the extent either Party is restricted by the licenses granted to the other Party and covenants contained herein, and to the extent permitted by law, each Party shall be entitled to practice
and sublicense Joint Inventions without restriction or an obligation to account to the other Party. Inventorship shall be determined in accordance with U.S. patent laws. 

    8.2 Prosecution of Patents. 

    (a) Amgen Patents.  [*] at InterMune's expense to the extent provided pursuant to Section 6.12 and, to the
extent Amgen elects to incur
additional expense for the further prosecution, defend or maintenance of such Amgen Patents, at Amgen's sole expense. [*] in the
jurisdictions of the Territory. To that end, [*] prior to the date such submission is proposed to be made, and will  [*] shall provide [*] with a copy of each submission to
a patent authority of a jurisdiction within the Territory regarding any Amgen Patent reasonably promptly after making such filing.  [*] discretion to abandon or not [*]
 any claim or patent
application within the Amgen Patents anywhere in the Territory, then [*] and shall provide  [*] claim or patent application in the Territory [*]
sole expense. 

    (b) Joint Patents. With respect to Joint Inventions, the parties shall
select and jointly retain mutually acceptable outside counsel to prosecute patent applications claiming such Joint Invention (any such patent application and any patents issuing therefrom a "Joint
Patent"). Each party must consent to any action taken with respect to the Joint Patents (which consent will not be withheld if withholding consent will, in the opinion of the retained outside counsel,
adversely affect the scope or validity of any patentable claims) on all such patent applications and patents and all correspondence to and from such patent offices, including proposed responses,
interferences and oppositions. Each Party shall bear its own internal costs, and the external costs for outside counsel, filing fees, etc. shall be borne equally by the Parties, except as provided in
the next sentence of this paragraph. Either Party may disclaim its interest in any particular Patent covering a Joint Invention, in which case (i) the disclaiming Party shall assign its
ownership interest in such Patent to the other Party for no additional consideration, (ii) the Party which is then the sole owner shall be solely responsible for all future costs of such
Patent, and (iii) the disclaiming Party shall have no further rights under such Patent. 

    8.3 Infringement of Patents and Trademarks by Third Parties. 

    (a) [*] the Amgen Trademarks and Amgen Patents
against Third Parties and to defend the Amgen Trademarks and Amgen Patents against any challenges in the Territory. In the event  [*] shall 

16

 

reasonably assist and cooperate in any such enforcement or defense. [*] all costs and expenses (including attorneys' fees)
incurred by [*] after the Effective Date to carry out the activities described in the foregoing two (2) sentences.
Recoveries in any actions under this Section 8.3(a) shall go first to reimburse the Parties' costs and expenses (including attorneys' fees) for such action and any remainder shall  [*]

    (b) [*] does not commence an enforcement and/or
defense action pursuant to Section 8.3(a) within [*] in writing or infringement of the Amgen Patents or Amgen Trademarks
in the Territory (or of the filing of a declaratory judgement action, in the case of defense actions), [*] shall be entitled to
bring and prosecute such an action [*]

    (c) Joint Patents. With respect to Third Party Infringement of Joint
Patents other than that Infringement described in Sections 8.5(b) and 8.5(c), the Parties shall confer and take such action, and allocate expenses and recoveries, in such manner as they shall agree. 

    8.4 Infringement of Third Party Rights.

    (a) Amgen as Named
Party.  [*] any action naming Amgen  [*] and claiming the infringement of (i) any Third Party Trademark through the
development or Commercialization of
Licensed Product; or (ii) Third Party Patent through the making, using, selling or having sold Licensed Product. The Parties shall confer with each other and cooperate during the defense of any
action in which both Amgen and InterMune are named parties. InterMune shall assist and cooperate with Amgen in the defense of any such action and if Amgen finds it necessary or desirable to join
InterMune as a party, InterMune shall execute all papers or perform such other acts as may reasonably be required by Amgen. [*]
be entitled to [*] and [*] in any  [*] [*] shall bear all associated costs and expenses (including attorneys'
fees) incurred after the
Effective Date and pay all damages and settlement amounts with respect to the Territory; provided, however, that  [*] shall have no obligation to bear such
costs and expenses and pay such damages and settlement amounts to the extent
attributable to [*] Licensed Products. 

    (b) InterMune as Named Party. InterMune  [*] any action which names InterMune but does not name Amgen and which
claims the infringement of (i) any Third Party
Trademark through the development or Commercialization of Licensed Product; or (ii) Third Party Patent through the using, selling or having sold Licensed Product. If necessary and at
InterMune's expense, Amgen will assist and cooperate with InterMune in any such defense. InterMune shall bear all costs and expenses (including attorneys' fees) and pay all damages and settlement
amounts with respect to the Territory, arising out of or in connection with any such action. 

    (c) Notice. Each Party shall promptly notify the other upon becoming
aware of (i) any Third Party claim or action against InterMune and/or Amgen for infringement of any Third Party Trademark through the development or Commercialization of Licensed Product; or
Third Party Patent through the using, selling or having sold Licensed Product; or (ii) any Third Party infringement of the Amgen Trademarks or Amgen Patents. 

    (d) Settlement. Neither Party shall enter into any settlement that
affects the other Party's rights or interests without such other Party's written consent, which consent shall not be unreasonably withheld or delayed. 

    8.5 Patent Marking. Licensed Products marketed and sold by InterMune
hereunder shall be marked with appropriate patent numbers or indicia at Amgen's request to the extent permitted by law in those countries of the Territory in which such markings have notice value as
against infringers of patents. 

17

 
ARTICLE 9

REPRESENTATIONS AND WARRANTIES  

    9.1 Mutual Representations and Warranties. Each Party hereby represents
and warrants to the other Party as follows: 

    (a) Corporate Existence and Power. As of the Effective Date, it is a
corporation duly organized, validly existing and in good standing under the laws of the state of Delaware, and has full corporate power and authority and the legal right to own and operate its
property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including, without limitation, the right to grant the licenses granted hereunder. 

    (b) Authority and Binding Agreement. As of the Effective Date,
(a) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all necessary corporate action on
its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder; and (c) the Agreement has been duly executed and delivered on behalf
of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with its terms. 

    (c) No Conflict. As of the Effective Date, the execution, delivery and
performance of this Agreement by such Party does not conflict with, and would not result in a breach of any agreement, instrument or understanding, oral or written, to which it is a party or by which
it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

    (d) Validity. As of the Effective Date, it is aware of no action, suit,
inquiry or investigation instituted by any Third Party which questions or threatens the validity of this Agreement. 

    9.2 Mutual Covenants. Each Party hereby covenants to the other Party as
follows: 

    (a) No Misappropriation. It shall not knowingly misappropriate the trade
secret of a Third Party in its activities to develop or Commercialize Licensed Products. 

    (b) No Debarment. In the course of the development and manufacture of
Licensed Products and during the Term, such Party shall not knowingly use and shall not have knowingly used any employee or consultant who is or has been debarred by the FDA or Regulatory Authorities,
or, to the best of such Party's knowledge, is or has been the subject of debarment proceedings by the FDA or Regulatory Authorities. 

    (c) No Conflict. It will not enter into any agreement with any Third
Party that is in conflict with this Agreement, and will not take any action that would in any way prevent it from assuming its obligations or granting the rights granted to the other Party under this
Agreement, or that would otherwise materially conflict with or adversely affect its obligations or assuming the rights granted to the other Party under this Agreement. 

    9.3 Representations, Warranties and Covenants of InterMune.

    (a) Expertise. In entering into this Agreement, InterMune has  [*]

    (b) Diligence. InterMune covenants to use  [*]

    (c) Compliance with Trademark Specifications. InterMune covenants to
maintain such reasonable quality standards as [*] in the use of the Amgen Trademarks to maintain the value of the Amgen
Trademarks. During the Term, InterMune shall provide, at the request of Amgen, representative samples of items bearing the Amgen Trademarks (including but not limited to Licensed Product brochures,
advertising and other promotional literature). 

18

 

    (d) Compliance by InterMune. InterMune covenants to comply with all
applicable statutes, regulations and guidance of Regulatory Authorities relating to the Commercialization and further development of the Licensed Products in each country in the Territory. 

    9.4 Representations, Warranties and Covenants of Amgen.

    (a) Representations and Warranties. Amgen represents and warrants to
InterMune as follows: 

19

 
    [*]

ARTICLE 10

INDEMNIFICATION  

    10.1 Indemnification by Amgen. Amgen hereby agrees to defend, hold
harmless and indemnify (collectively "Indemnify") InterMune and its Affiliates, agents, directors, officers and employees (the "InterMune Indemnitees") from and against any and all Losses arising out
of (i) any Third Party claims resulting directly or indirectly out of any of Amgen's representations and warranties set forth in this Agreement being untrue in any material respect when made or
any material breach or material default by Amgen of [*] To be eligible to be so Indemnified, the InterMune Indemnitees shall
provide Amgen with prompt notice of any claim giving rise to the indemnification obligation pursuant to this Section 10.1 and the exclusive ability to defend (with the reasonable cooperation of
InterMune Indemnitees) and subject to InterMune's right to participate in and have counsel selected by it participate, at InterMune's expense, in any action for which InterMune seeks to be Indemnified
by Amgen). InterMune shall not settle any claim for the Loss associated with which any InterMune Indemnitee seeks to be Indemnified by Amgen, without Amgen's prior written consent,  provided that the
Indemnitor shall be relieved of its obligations only if the failure by the Indemnitee to deliver prompt notice shall have been
prejudicial to its ability to defend such action. Amgen's obligation to Indemnify the InterMune Indemnitees pursuant to this Section 10.1 shall not apply to the extent of any Losses
(i) that arise from the negligence or intentional misconduct of any InterMune Indemnitee; (ii) that arise from InterMune's breach of this Agreement; or (iii) for which InterMune
is obligated to Indemnify the Amgen Indemnitees pursuant to Section 10.2 of this Agreement [*]

    10.2 Indemnification by InterMune. InterMune hereby agrees to Indemnify
Amgen and its Affiliates, agents, directors, officers and employees (the "Amgen Indemnitees") from and against any and all Losses arising from Third Party claims resulting directly or indirectly from
(i) any of InterMune's representations and warranties set forth in this Agreement (including without limitation the Supply Terms) being untrue in any material respect when made or any material
breach or material default by InterMune of [*]; or (ii) the making, having made, using, selling, having sold, offering
for sale, or resale and/or otherwise distributing of Licensed Products by, on behalf of, or under the authority of InterMune, its Affiliates or any of its
Sublicensees. Without limiting the foregoing, InterMune agrees to Indemnify the Amgen Indemnitees from any Losses arising from, relating to, or based
upon any claim by a Third Party that a Licensed Product was or is [*] or a Licensed Product caused any death or personal injury
of any kind, including but not limited to any death or personal injury occurring during the conduct of any clinical trial by, on behalf of, or under the authority of InterMune, its Affiliates or
Sublicensees. To be eligible to be Indemnified as described above in this Section 10.2, The Amgen Indemnitees shall provide InterMune with prompt notice of any claim giving rise to the
indemnification
obligation pursuant to this Section 10.2 and the exclusive ability to defend (with the reasonable cooperation of Amgen Indemnitees and subject to Amgen's right to participate in and have
counsel selected by it participate, at Amgen's expense, in any action for which Amgen seeks to be Indemnified by InterMune). Amgen shall not settle any claim for the Loss associated with which any
Amgen Indemnitee seeks to be Indemnified by InterMune, without InterMune's prior written consent, provided that InterMune shall be relieved of its obligations only if the failure by the Amgen
Indemnitee to deliver prompt notice shall have been prejudicial to its ability to defend such action. InterMune's obligation to Indemnify the Amgen Indemnitees pursuant to this Section 10.2
shall not apply to the extent of any Losses (i) that arise from the negligence or intentional misconduct of any Amgen Indemnitee [ *  ], (ii) for
which Amgen is obligated to Indemnify the InterMune Indemnitees pursuant to Section 10.1 of this Agreement or the
Supply Terms, or (iii) that arise from any material breach by Amgen of this Agreement [*]

    10.3 Insurance. Within thirty (30) days of the Effective Date,
each Party shall at its own expense procure and maintain during the Term, insurance policy/policies, including product liability insurance, 

20

 

adequate to cover its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated. Amgen may self-insure and InterMune may, with
the Amgen's prior written consent, self-insure all or part of any such obligation consistent with pharmaceutical industry practices. Each insurance policy required by, and procured under,
this Section 10.3 by InterMune shall name Amgen as an additional insured. Such insurance shall not be construed to create a limit of the insuring Party's liability with respect to its
indemnification obligations under this Article 10. InterMune shall provide Amgen with written evidence of such insurance upon request. InterMune shall provide Amgen with written notice at least
thirty (30) days prior to the cancellation, non-renewal or material change in such insurance or self-insurance which materially adversely affects the rights of Amgen
hereunder. 

    10.4 Pre-Effective Date Losses. In connection with this
Agreement, InterMune is not assuming or liable for any Losses resulting from or arising in connection with the use, marketing, sale, manufacture, distribution or promotion of any Licensed Product on
or prior to the Effective Date. In addition, InterMune shall not assume or be liable for any Losses whatsoever related to acts or omissions relating to the Licensed Product occurring prior to the
Effective Date. 

    10.5 Limitation of Liability. NEITHER PARTY NOR ITS RESPECTIVE
AFFILIATES AND PERMITTED SUBLICENSEES SHALL BE LIABLE FOR SPECIAL, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE INCURRED BY THE
OTHER PARTY IN CONNECTION WITH THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO DAMAGES MEASURING LOST PROFITS OR BUSINESS OPPORTUNITIES. NOTWITHSTANDING THE FOREGOING, AMOUNTS PAID BY A PARTY TO A THIRD
PARTY AS SPECIAL, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY OR OTHERWISE SHALL BE REIMBURSED SUCH PARTY BY THE OTHER PARTY TO THE
EXTENT SUCH OTHER PARTY IS REQUIRED TO INDEMNIFY SUCH FIRST PARTY PURSUANT TO THE INDEMNIFICATIONS OF SECTION 10.2 OR 10.1. 

ARTICLE 11

RECORDS; ROYALTY AUDIT; PUBLICATIONS  

    11.1 Records; Royalty Audit. InterMune shall keep or cause to be kept
such records as are required to determine, in a manner consistent with GAAP, the accuracy of calculations of all sums or credits due under this Agreement. Such records shall be retained for no less
than a [*] period following the year in which any payments were made hereunder. Once per calendar year, Amgen shall have the
option to engage, at its own expense, an independent certified public accountant appointed by Amgen and reasonably acceptable to InterMune, to examine, in confidence, the records of InterMune as may
be necessary to determine, with respect to any calendar year, the correctness or completeness of any report or payment required to be made under this Agreement. The report of such accountant shall be
limited to a certificate verifying any report made or payment submitted by InterMune during such period but may include, in the event the accountant shall be unable to verify the correctness of any
such payment, information relating to why such payment is unverifiable. All information contained in any such certificate shall be deemed Confidential Information hereunder. If any audit performed
under this Section 11.1 discloses a variance of more than [*] from the amount of the original report, Royalty or payment
calculation, InterMune shall bear the full cost of the performance of such audit. 

    11.2 Publications" Prior to oral or written presentation or submission
for publication of any data or information relating to Licensed Products, each Party agrees to provide the other Party the opportunity to review any proposed presentations or publication at least  [*] to
their intended submission for publication for its Confidential Information and each Party shall remove the Confidential
Information of the other Party from any proposed publication or presentation upon request by such other Party. Amgen will [*]
permission from each [*] relating to Infergen, and shall be  [*] to review InterMune's publications relating 

21

 

to Infergen. Any such publications that Amgen discloses to InterMune shall be treated as Amgen Confidential Information hereunder, and Amgen shall only disclose any such publications of InterMune's to
Other Licensees that agree to be bound by confidentiality and non-use obligations commensurate with those contained herein. 

ARTICLE 12

CONFIDENTIALITY  

    12.1 Treatment of Confidential Information. The Parties agree that
during the Term, and for a period of five (5) years after this Agreement expires or terminates, a Party receiving Confidential Information of the other Party shall (i) maintain in
confidence such Confidential Information to the same extent such Party maintains its own proprietary industrial information of similar kind and value (but at a minimum each Party shall use
commercially reasonable efforts to maintain Confidential Information in confidence); (ii) not disclose such Confidential Information to any Third Party without prior written consent of the
disclosing Party, except for disclosures to its licensees, sublicensees and commercial partners for Licensed Products who agree to be bound by obligations of non-disclosure and
non-use at least as stringent as those contained in this Article 12; and (iii) not use such Confidential Information for any purpose except those purposes permitted by this
Agreement Amgen shall not knowingly disclose to InterMune any Third Party information or Know-How that Amgen does not have the legal right to disclose to InterMune and/or has a contractual
obligation not to disclose to InterMune. 

    12.2 Authorized Disclosure. Notwithstanding any other provision of this
Agreement, each Party may disclose Confidential Information of the other Party: 

    (a) to the extent and to the persons and entities as required by an applicable law, rule, regulation, legal process,
court order or the rules of the National Association of Securities Dealers or of a Regulatory Authority; or 

    (b) as necessary to file or prosecute those patent applications for which either Party has the right to assume
prosecution or maintenance, pursuant to Section 8.2(b) of this Agreement (in the case of Amgen's Confidential Information), prosecute or defend litigation or otherwise establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary. 

provided, however, that the Party required or intending to disclose the other Party's Confidential Information under Sections 11.2(a) or
(b) shall first have given prompt notice to such other Party to enable it to seek any available exemptions from or limitations on such disclosure requirement and shall reasonably cooperate in
such efforts by the other Party. 

    12.3 Publicity; Terms of Agreement. The Parties agree that the existence
of and the material terms of this Agreement shall be considered Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth below in this
Section 12.3 (in lieu of the authorized disclosure provisions set forth in Section 12.2, to the extent of any conflict) and without limiting the generality of the definition of
Confidential Information set forth in Section 1.12. The Parties will mutually agree the text of a press release
announcing the execution of this Agreement. Thereafter, if either Party desires to make a public announcement concerning this Agreement or the terms hereof, such Party shall give reasonable prior
advance notice of the proposed text of such announcement to the other Party for its prior review and approval, such approval not to be unreasonably withheld. A Party shall not be required to seek the
permission of the other Party to repeat any information as to the terms of this Agreement that have already been publicly disclosed by such Party in accordance with the foregoing or by the other
Party. Either Party may disclose the terms of this Agreement to potential investors who agree to be bound by obligations of non-disclosure and non-use at least as stringent as
those contained in this Article 12. The Parties acknowledge that Amgen and/or InterMune may be obligated to file a copy of this Agreement with the U.S. Securities and Exchange Commission
with its next quarterly report on Form 10-Q, annual report on Form 10-K or current report on Form 8-K or with any registration statement filed
with the U.S. Securities 

22

 

and Exchange Commission (the "SEC") pursuant to the Securities Act of 1933, as amended and each such Party shall be entitled to make such filing,  provided that it requests confidential treatment of the
more sensitive terms hereof to the extent such confidential treatment reasonably available to
the filing Party under the circumstances then prevailing. In the event of any such filing, the filing Party will provide the non-filing Party with an advance copy of the Agreement marked
to show provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider the non-filings Party's timely comments thereon. 

ARTICLE 13

TERM AND TERMINATION  

    13.1 Term. This Agreement shall become effective on the Effective Date
and shall remain in effect, unless earlier terminated pursuant to this Article 13, until the expiration of the later to expire of the last Valid Claim within the Amgen Patents claiming the use
or sale of Licensed Product in the Territory. 

    13.2 Discontinuation of Commercialization or Further Development. In the
event InterMune shall at any time elect to discontinue all Commercialization and development activities relating to Licensed Products, InterMune shall notify Amgen in writing of such election and upon
Amgen's receipt of such notification, this Agreement shall terminate and all licenses under the Amgen Technology granted to InterMune hereunder shall revert to Amgen. 

    13.3 Termination for Default. 

    (a) InterMune. Upon any Default by InterMune under this Agreement Amgen
may notify InterMune of such Default and, in the event such Default shall be a payment Default, require that InterMune cure such Default within  [*] days of Amgen's notice, or in the event such Default
shall be a Default other than a payment Default, require that InterMune
cure such Default within [*] days of Amgen's notice, or, if such Default (other than a payment Default) cannot reasonably be
cured within such time period, present a reasonably achievable plan to cure such Default as promptly as is reasonably practicable under the circumstances. In the event InterMune shall not have cured
the Default at the end of the applicable grace period, Amgen may terminate this Agreement, and all licenses and assignments granted hereunder to InterMune, its Affiliates and Sublicensees, shall
revert to Amgen. Upon termination of this Agreement pursuant to this Section 13.3(a), InterMune shall immediately cease all development and Commercialization of the Licensed Products, return to
Amgen all physical manifestations of the Amgen Technology, and promptly take all actions reasonably necessary to effect the transfer to Amgen of all Regulatory Approvals for Infergen in the Territory
(including without limitation by making such filings as may be required with Regulatory Authorities and other governmental authorities of the Territory that may be necessary to effect such transfer). 

    (b) Amgen. Upon any Default by Amgen under this Agreement, InterMune may
notify Amgen in writing of such Default and require that Amgen cure such Default within [*] days, or, if such Default cannot
reasonably be cured within such time period, present a reasonably achievable plan to cure such Default as promptly as is reasonably practicable under the circumstances. In the event Amgen shall not
have cured the Default at the end of the [*] grace period, InterMune may  [*] or (ii) terminate this Agreement effective upon a second written notice
to Amgen. If Amgen fails to cure a Default as
described in clause (i) of the foregoing sentence within [*] after such written notice, then any  [*] and InterMune shall be relieved of its
obligations pursuant to  [*] but the other provisions of this Agreement (including without limitation Section 6.4) shall remain in full force and
effect. 

    13.4 Licenses Upon Expiration. InterMune's licenses pursuant to Sections
2.2, 2.3 and 2.4 shall, upon expiration of this Agreement as provided in Section 13.1 shall automatically convert to being irrevocable and fully paid. Sections 3.1, 3.6, 4.1, 4.2, 4.3,
4.5, 4.6, and 4.8 shall survive expiration of this Agreement. 

23

 

    13.5 Survival. The following provisions shall survive any expiration or
termination of this Agreement for the period of time specified: Articles 10, 11, 12, 13, 14 and 15 and Sections 2.1, 4.4, 4.7, 8.1, 8.2(b), 8.3 and 8.4
(but only with respect to infringement during the Term), Termination of this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of such
termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party's right
to obtain performance of any obligation. The remedies provided in this Article 13 are not exclusive of any other remedies a Party may have in law or equity, subject to the Section 13.6
as it applies to the limited category of Defaults described therein. 

    13.6 Determination of PEG Diligence. If at any time following the
Planning Period Date Amgen believes that InterMune is not meeting its diligence obligations pursuant to Sections 3.3 or 5.2(b), then Amgen may so notify InterMune in writing and the Parties
will meet to discuss the situation in good faith. If after such discussions, Amgen continues to believe that InterMune has not met its diligence obligations pursuant to such Sections, then Amgen may  [*]
pursuant to [*] solely to the extent pertaining to  [*] and Amgen shall be entitled to [*] in the Territory
 [*] provided, however, that if InterMune disagrees as to whether it has met such diligence obligations,
then the matter shall be resolved in accordance with Article 14, and [*] hereunder shall  [*] until such dispute is resolved (if it is resolved in
favor of Amgen). Notwithstanding anything to the contrary express or
implied in this Agreement, the remedy provided pursuant to this Section 13.6 shall be Amgen's exclusive remedy (including without limitation to the exclusion of any remedies provided pursuant
to Section 13.2) for InterMune Defaults relating to InterMune's diligence obligations with respect to a PEG-Infergen Product pursuant to Sections 3.3 and 5.2(b). 

ARTICLE 14

DISPUTE RESOLUTION  

    14.1 Disputes. The Parties recognize that disputes as to certain matters
may from time to time arise during the term of this Agreement which relate to either Party's rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to
facilitate the resolution of disputes arising from, concerning or in any way relating to this Agreement in an expedient manner by mutual cooperation and without resort to litigation. To accomplish
this objective, the Parties agree to follow the procedures set forth in this Section 14.1 if and when a dispute arises under this Agreement. The Parties shall undertake good faith efforts to
resolve any such dispute in good faith. In the event the Parties shall be unable to resolve such dispute, either Party may, by written notice to the other Party, have any dispute between the Parties
remaining unresolved after thirty (30) days referred to their respective executive officers designated below or their designees or successors for attempted resolution by good faith negotiations
within thirty (30) days after such notice is received. Such designated officers are as follows: 

For InterMune: InterMune's General Counsel  

 For Amgen: Amgen's General Counsel  

If the designated officers are not able to resolve such dispute within such thirty (30) day period, either Party may at any time thereafter pursue any legal or equitable
remedy available to it. Notwithstanding the above, either Party shall be entitled at all times and without delay to seek equitable relief. 

    14.2 Governing Law; Judicial Resolution. Resolution of all disputes
arising out of or related to this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the
substantive laws of the State of California, as applied to agreements executed and performed entirely in the State of California by residents of the State of California, without regard to conflicts of
law rules. Any dispute arising under this Agreement shall be submitted to a state or federal court of competent jurisdiction in California; provided however, that if 

24

 

Amgen is the initiating Party in a dispute, such suit shall be brought in a state or federal court which has jurisdiction over Burlingame, California; and if InterMune is the initiating Party in a
dispute, such suit shall be brought in a state or federal court which has jurisdiction over Thousand Oaks, California. 

    14.3 Patent and Trademark Dispute Resolution. Any dispute, controversy
or claim relating to the scope, validity, enforceability or infringement of any patent rights claiming the use or sale of any Licensed Product or of any Trademark rights relating to Licensed Product
shall be submitted to a court of competent jurisdiction in the Territory in which such patent or trademark rights were granted or arose. Notwithstanding the foregoing, any dispute, controversy or
claim relating to the scope, validity, enforceability or infringement of any United States patent rights covering the use or sale of any Licensed Product shall be submitted to a court of competent
jurisdiction in the State of California. To the extent permitted by law, InterMune agrees that it shall not dispute the scope, validity, enforceability or infringement of any patent right outside the
United States which claims the use or sale of any Licensed Product. 

ARTICLE 15

MISCELLANEOUS  

    15.1 Entire Agreement; Amendment. This Agreement (including all
Exhibits), the Confidential Disclosure Agreement dated March 9, 2001, and the Exclusive Dealings Binder dated April 12, 2001 set forth the complete, final and exclusive agreement and all
the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and terminates all prior agreements and understandings between
the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and
therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

    15.2 Force Majeure. Both Parties shall be excused from the performance
of their obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of the prevention to the other Party.
Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party uses reasonable efforts to remove the condition. 

    15.3 Notices. Any notice required or permitted to be given under this
Agreement shall be in writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail,
postage prepaid, express delivery service or 

25

 

personally delivered, or if sent by facsimile, electronic transmission confirmed. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below. 

	For InterMune:	 	InterMune, Inc.

1710 Gilbreth Road, Suite 301

Burlingame, CA 94010-1317

Facsimile: (650) 259-0774

Attn: General Counsel
	

With a Copy to:	
 	

Cooley Godward LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306

Fax: (650) 849-7400

Attention: Robert L. Jones, Esq.
	

For Amgen:	
 	

Amgen, Inc.

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Fax: (805) 499-8011

Attention: Vice President, Licensing

With a Copy to: Corporate Secretary

    15.4 Maintenance of Records. Each Party shall keep and maintain all
records required by law or regulation with respect to Licensed Products and shall make copies of such records available to the other Party upon request. 

    15.5 No Strict Construction. This Agreement has been prepared jointly
and shall not be strictly construed against either Party. 

    15.6 Assignment. Neither Party may assign or transfer this Agreement or
any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party's consent to Affiliates or to an entity that
acquires all or substantially all of the business of such Party, whether in a merger, consolidation, reorganization, acquisition, sale or otherwise. This Agreement shall be binding on the successors
and assigns of the assigning Party, and the name of a Party appearing herein shall be deemed to include the name(s) of such Party's successors and permitted assigns to the extent necessary to carry
out the intent of this Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.6 shall be null and void and of no legal effect. 

    15.7 Performance by Affiliates. Each of Amgen and InterMune acknowledge
that obligations under this Agreement may be performed by Affiliates of Amgen and InterMune. Each of Amgen and InterMune guarantee performance of this Agreement by its Affiliates, notwithstanding any
assignment to Affiliates in accordance with Section 15.6 of this Agreement. Wherever in this Agreement the Parties delegate responsibility to Affiliates or local operating entities, the Parties
agree that such entities may not make decisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way. 

    15.8 Counterparts. This Agreement may be executed in two (2) or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

    15.9 Severability. If any one or more of the provisions of this
Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall
not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable 

26

 

provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

    15.10  Headings. The headings for each article and section in this
Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

    15.11  Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

    15.12  Independent Contractors. The relationship between InterMune and
Amgen created by this Agreement is one of independent contractors and neither Party shall have the power or authority to bind or obligate the other except as expressly set forth in this Agreement. 

    15.13  Use of Name. No right, express or implied, is granted to either
Party by this Agreement to use in any manner any Trademark (except the Amgen Trademarks as set forth in this Agreement) of the other Party, including the names "Amgen" and "InterMune", without the
prior written consent of the owning Party, subject to Section 12.3. 

    15.14  No Waiver. Any delay in enforcing a Party's rights under this
Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party's rights to the future enforcement of its rights under this Agreement, except with
respect to an express written and signed waiver relating to a particular matter for a particular period of time. 

    In Witness Whereof, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of the
Effective Date. 

	Amgen Inc.	 	InterMune, Inc.
	

By:	
 	

/s/ SCOTT J. FORAKER   
	
 	

By:	
 	

/s/ JOHN J. WULF   

	Print Name:	 	Scott J. Foraker	 	Print Name:	 	John J. Wulf
	Title:	 	Vice President, Licensing	 	Title:	 	Senior Vice President of Corporate Development

27

Exhibit A

Amgen Trademarks  

[*]

INFERGEN  

	3)	 	Country:	 	US
	 	 	Appln. Date:	 	8/13/93
	 	 	Appln. No.:	 	74/424795
	 	 	Reg. Date:	 	11/7/95
	 	 	Reg. No.:	 	1933729
	 	 	Goods:	 	Pharmaceutical preparation namely interferon for use in the treatment of viral, neoplastic and autoimmune diseases.
	

4)	
 	

Country:	
 	

Canada
	 	 	Appln. Date:	 	9/1/93
	 	 	Appln. No.:	 	736130
	 	 	Reg. Date:	 	7/21/95

Exhibit B

Amgen Patents as of the Effective Date  

[*]

[*]

Exhibit C

Protein Sequence of [*]  

[*]

Exhibit D

Regulatory Approvals for Infergen as of the Effective Date  

United States  

BLA
for HCV treatment—October 6, 1997

Supplement for SingleJect prefilled syringe—January 6, 1999

Supplement for 48-week retreatment—December 22, 1999

Supplement for geriatric language—August 10, 2000 

Canada  

BLA
for HCV treatment—March 9, 1999 

Exhibit E

Ongoing Clinical Trials  

	[*]	 	[*]
	[*]	 	[*]
	[*]	 	[*]

Exhibit F

Supply Terms  

	•
	Supply of Infergen.

    Amgen
shall supply InterMune with InterMune's requirements of Infergen for development and commercialization in the Licensed Territory in accordance with the terms of this
Exhibit F (the "Supply Terms"). 

	•
	Term.

    The
term of Amgen's supply obligation hereunder shall expire on the earlier of: (1) the date on which InterMune receives Regulatory Approval to market Infergen obtained
pursuant to a supply agreement [*] Third Party for supply of Infergen in the Licensed Territory; (2) the date on which
InterMune receives Regulatory Approval to market Infergen manufactured by InterMune or a Third Party of its choice [*] the
effective date of termination of the License and Commercialization Agreement [*] January 1, 2015. 

	•
	Effect of Expiration or Termination. [ *  ] in addition to any all other accrued but unpaid payments due Amgen from
InterMune, and Amgen will be obligated to deliver to InterMune all
such firm orders paid for. 

	•
	Transfer of Manufacturing Rights.

	•
	Amgen's Third Party Contractor. Amgen may assign or sublicense any of its rights or obligations under this
Exhibit F to a Third Party contractor, provided that if such assignment or sublicense is made to a Third Party other than  [*], Amgen shall first obtain InterMune's prior written consent (not to be
unreasonably withheld). Amgen shall continue to
supply Infergen to InterMune in accordance with the Supply Terms until such time as InterMune receives all necessary Regulatory Approvals in the Licensed Territory to market Infergen manufactured by
such Third Party contractor. [*]  associated with all work necessary to obtain Regulatory Approval for InterMune
to market Infergen manufactured by [*]  as applicable.

	•
	InterMune and its Third Party Contractor. [*]  InterMune will be
responsible for paying all costs associated with all work necessary for InterMune to obtain Regulatory Approval to market Infergen manufactured by InterMune. 

	•
	Form of Supply. 

    Infergen
shall be supplied in the following forms only: 

	•
	[*]

	•
	[*]

	•
	[*]

	•
	Packaging and Labeling. As of the Effective Date, Amgen has in its inventory certain quantities of  [*]  Infergen,
labeled and packaged for commercial sale in the Territory (the "Amgen Infergen Inventory") from
which initial orders of Infergen placed by InterMune will be filled. When the Amgen Infergen Inventory is exhausted, InterMune shall thereafter be responsible for and bear all costs associated with
the design, development, quality release and Regulatory Approval of all labeling and packaging materials for Infergen supplied hereunder for commercial sale. InterMune shall perform its  [*]  InterMune shall be solely responsible for labeling and packaging Infergen for clinical trial use. 

	•
	Supply Price; Third Party Royalties; Statements and Payments.

	•
	Infergen Supply Price

    Amgen
shall supply Infergen to InterMune at the following prices: 

	•
	[*]  

              [*]

    "Standard
Cost" shall mean and include the following cost elements incurred by Amgen: [*]

	•
	Additional Work. If at InterMune's written request and upon Amgen's written consent Amgen performs any work
or activities outside the scope of filling purchase orders placed by InterMune pursuant to paragraph 6.3, or if Amgen is required by a Regulatory Authority in the Licensed Territory to perform
work not necessitated by or arising from Amgen's negligence in performing its obligations hereunder, then  [*]  Any work performed or to be performed by Amgen which is necessitated by or arises
from Amgen's negligence in
performing its manufacture and supply obligations hereunder, including but not limited to work required by a Regulatory Authority in the Licensed Territory  [*]

	•
	Third Party Royalties. For purposes of this Section 5.3, "Third Party Payments" shall mean  [*]

	•
	[*]

	•
	During
the term of Amgen's supply obligation hereunder, [*]

	•
	Statements and Payments. Amgen shall, on an as delivered basis, provide InterMune with a statement setting
forth quantities of Infergen delivered, the supply price, the amount of any Third Party royalties and costs for additional work, if any. Payments shall be due from InterMune within  [*]  following the date of receipt of such shipment at InterMune's designated facility. Delivery costs shall be
paid directly by InterMune to its designated carrier. 

	•
	Forecasts/Orders.

	•
	Amgen Infergen Inventory.

    Promptly
after execution of the License and Commercialization Agreement, Amgen will provide to InterMune a report showing Amgen's then-current inventory levels of Amgen
Infergen Inventory. InterMune shall specify by binding written firm purchase order its reasonable requirements of Amgen Infergen Inventory not later than  [*]

	•
	Rolling Forecasts.

	•
	InterMune
will determine its good faith projected Infergen supply needs, taking into consideration the Amgen Infergen Inventory levels, and will deliver
the first rolling forecast for the [*]  months prior to the requested delivery date for InterMune's first firm
order of Infergen to be supplied from Infergen manufactured for InterMune (i.e., not Amgen Infergen Inventory). For each quarter of the rolling forecast, InterMune shall specify the quantity and form
per quarter of its future needs of Infergen. Following submission of this first forecast, the forecast shall be amended quarterly (no later than the first day of a calendar quarter)
to: (1) add a forecast for the next successive calendar quarter for which no forecast has been submitted and
(2) [*]  Each quarterly forecast shall be  [*]

	•
	Not
later than [*]  days after Amgen's receipt of each rolling
forecast, Amgen will confirm in writing that it can manufacture and supply the quantities specified in the forecast in the quarters specified therein (the "Forecast Confirmation").  [*]  Promptly thereafter the Parties shall discuss in good faith  [*]  If, at any time after Amgen submits to InterMune its Forecast Confirmation, Amgen  [*]  Amgen shall so notify InterMune in writing and the Parties shall discuss in good faith such proposed
arrangements and other appropriate means to ensure an uninterrupted supply of Infergen to InterMune consistent with its forecast.  [*]

	•
	Firm Orders. InterMune shall specify by binding written firm purchase order its reasonable requirements of
Infergen for each calendar quarter at least [*]  in advance of each such calendar quarter (collectively "Firm
Purchase Orders"). Each Firm Purchase Order shall specify: the quantity [*]  and the delivery date. In no event
shall a Firm Purchase Order be 

more
or less than the amount specified for such applicable quarter in the Rolling Forecast. Amgen will [*] Infergen to InterMune
in response to Firm Purchase Orders. For as long as Amgen continues to manufacture Infergen [*] Amgen's manufacturing capacity
for Infergen for such period, provided however that InterMune may order and Amgen shall supply Infergen in quantities up to  [*]

	•
	Product Specifications; Noncompliant Goods; Inspections.

	•
	cGMP. Infergen supplied by Amgen hereunder will be manufactured in accordance with current Good
Manufacturing Practices (as defined in the Code of Federal Regulations) and the manufacturing process approved by the relevant Regulatory Authorities in the Licensed Territory. Infergen shall be
manufactured by Amgen in a facility approved by applicable Regulatory Authorities. Amgen shall be responsible for keeping such facility and the manufacturing processes for Infergen in compliance with
current Good Manufacturing Practices.

	•
	Shelf Life. [*]

	•
	Product Specifications and Manufacturing Process. Amgen will supply Infergen which complies with the
product specifications and the manufacturing process approved by the relevant Regulatory Authorities in the Licensed Territory (collectively, the "Specifications"). For so long as InterMune purchases
Infergen from Amgen under the terms and conditions set forth herein, no changes to the Specifications may be made without each Party's prior written consent (which may be withheld in either Party's
sole discretion, provided  that no consent shall be needed from InterMune in order for Amgen to make changes (i) as required by
the relevant Regulatory Authorities in the Licensed Territory or (ii) to comply with current Good Manufacturing Practices).  [*]  Amgen shall notify InterMune in writing of any changes in
or to the Specifications, Amgen's manufacturing
facilities or procedures, vendors, raw materials or capital equipment that will or may require InterMune to amend the BLA for Infergen or otherwise fulfill InterMune's regulatory obligations.

	•
	Product Release. Amgen shall be responsible for the manufacturer's release of Infergen. Amgen will provide
to InterMune upon release of each lot of Infergen complete and accurate certificates of analysis, certificates of compliance, and deviations and their investigations (the "Disposition Package"). As
InterMune may request from time to time, Amgen will make batch records relating to fermentation, bulk Infergen, Infergen for fill and finish manufacturing and packaging available for InterMune's
inspection, which records shall be complete and accurate.

	•
	Testing and Noncompliant Goods. Amgen and InterMune shall agree on a mutually acceptable Third Party to
conduct testing of Infergen for compliance with Specifications, and Amgen and InterMune will each be entitled to a complete copy of all testing data. InterMune shall have  [*]  from receipt of
all requested records, in which to (i) review the Disposition Package, and upon
InterMune's request, the relevant batch records, provided pursuant to Subsection 7.4 above; (ii) test a shipment of Infergen for compliance with Specifications, and (iii) notify Amgen in
writing of any noncompliant Infergen, including but not limited to Infergen manufactured using a manufacturing process not approved by the relevant Regulatory Authority. Amgen shall cooperate with
InterMune in good faith to determine whether such rejection is justified. [*]

	•
	Final Product Lot Release.  [*]  shall be solely responsible for final lot release of Infergen
for all uses (including but not limited to
review of the Disposition Package and batch records, and such testing as [*]  may elect to perform to ensure the
final quality assurance and quality control and conformance of such lots to the lot release specifications of all applicable Regulatory Authorities).

	•
	Inspections. In addition to its review of the Disposition Package pursuant to subsection 7.4 above,
InterMune may visit and inspect and audit, at its own expense, [*]  in each case in so far as such facilities or
records relate solely to the Infergen supplied hereunder. Information obtained by InterMune in the course of such inspections shall be treated as Confidential 

Information,
provided however that InterMune may disclose such Confidential Information to the extent necessary to comply with applicable law or regulations or other requirements of the relevant
Regulatory Authorities in the Licensed Territory. Inspections conducted hereunder will be limited in scope to what is reasonably necessary to confirm that Amgen has complied with current Good
Manufacturing Practices in manufacturing and labeling and packaging Infergen supplied to InterMune hereunder. InterMune may conduct inspections no more frequently than  [*]  InterMune will
coordinate all inspections of manufacturing facilities relating to Infergen with Amgen and
provide Amgen with [*]  Amgen shall respond in writing with an action plan for corrective and preventative
actions [*]  Amgen shall reasonably cooperate with applicable Regulatory Authorities with respect to inspections. 

	•
	Know-How. Except as expressly set forth in the License and Commercialization Agreement, Amgen
shall have no obligation to disclose to InterMune, and InterMune shall have no rights with respect to, any Amgen Know-How, including but not limited to that pertaining to the Manufacturing
Know-How relating to Infergen; [*]

	•
	Disclaimer.  OTHER THAN THE EXPRESS WARRANTIES SPECIFICALLY SET FORTH IN SUBSECTIONS 7.1,
7.2 AND 7.3 ABOVE, AMGEN MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND AND HEREBY DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED, WITH RESPECT TO
ITS SUPPLY OF INFERGEN TO INTERMUNE.

	•
	Stability.  [*]

	•
	Shipment and Delivery.All Infergen supplied by Amgen will be delivered to  [*]  InterMune shall be responsible for
all delivery logistics, delivery validation, insurance and compliance
with laws and regulations (including but not limited to those applicable to the export of each [*]  delivery from
the United States to Canada) and all costs associated with any of the foregoing. [*]

	•
	Compliance With Laws.

    Subject
to paragraph 5.2, Amgen shall be responsible for complying with applicable laws and regulations relating to the manufacture of Infergen supplied to InterMune hereunder.
Amgen has and shall maintain all necessary government permits, including without limitation, health and safety and environmental permits necessary for the conduct of the actions it undertakes pursuant
to its supply obligations hereunder. 

	•
	Breach of Supply Obligation

    If
Amgen fails to timely supply material quantities of Infergen in accordance with Firm Purchase Orders (other than by reason of force majeure) or supplies material quantities of
Infergen in material breach of paragraphs 7.1, 7.2, or 7.3, then [*]

	•
	Additional Agreements.

	•
	[*]

	•
	Supply of Licensed Product. This Exhibit F governs solely the supply of Infergen. The Parties shall
negotiate in good faith a separate supply agreement for the supply of Licensed Products other than Infergen. 

	•
	Definitions.All capitalized terms not otherwise defined herein shall have the meaning assigned to them in
the License and Commercialization Agreement.

	•
	Formulating Know-How  means Amgen's  [*]

	•
	Manufacturing Know-How  means any Know-how  [*]

	•
	Manufacturing Patents  mean any Patents  [*]

	•
	Amgen Manufacturing Technology  means Manufacturing Know-how and Manufacturing
Patents. 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

QuickLinks

Exhibit 10.39

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]